

01-03-00

A

EXPRESS MAIL CERTIFICATE

Date 12/30/99 Label No. EM 595860757

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner of Patents & Trademarks, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

X. DiLU110 X. DiLU110
Name (Print) Signature

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

DARBY & DARBY P.C.

805 Third Avenue
New York, New York 10022
212-527-7700

Docket No: 2427/1E988-US1

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:


Enclosed please find an application for United States patent as identified below:

Inventor/s (name ALL inventors): Vincent J. KIDD, Memphis, TN;
Jill M. LAHTI, Memphis, TN; and
Tal TEITZ, Cordova, TN

Title: A TUMOR SUPPRESSOR PROTEIN INVOLVED IN DEATH SIGNALING, AND
DIAGNOSTICS, THERAPEUTICS, AND SCREENING BASED ON THIS
PROTEIN

including the items indicated:

1. Specification and 47 claims: 8 indep.; 39 dep.; 0 multiple dep.
2. ☐ Executed declaration and power of attorney
☒ Unexecuted declaration and power of attorney



3. ☐ Formal drawings, _ sheets (Figs.)
☒ Informal drawings, fourteen (14) sheets (Figs. 1-8)
4. ☐ Assignment for recording to:
5. ☐ Verified Statement Claiming Small Entity Status
6. ☐ Check in amount of \$.00, (\$ filing; \$ recording; \$ surcharge)
(See attached **Fee Computation Sheet**)
7. ☐ Preliminary Amendment.
8. ☒ Please amend the description by inserting the following paragraph after the line containing the title on page 1:
"This patent application claims the priority of U.S. provisional patent application No. 60/114,308, filed December 31, 1998, which is incorporated herein by reference."

Priority is claimed for this application, corresponding application/s having been filed as follows:

Country:

Number:

Date:

The priority documents ☐ are enclosed
☐ will follow.

Respectfully submitted,



Paul F. Fehlner, Ph.D.

Reg. No. 35,135

Attorney for Applicant(s)

EXPRESS MAIL CERTIFICATE

Date 12/30/99 Label No. EM595860757

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 by "Express Mail Post Office to Addressee" service.

A. DiLullo
Name (Print)

A. DiLullo
Signature

2427/1E988-US1

**A TUMOR SUPPRESSOR PROTEIN INVOLVED IN DEATH
SIGNALING, AND DIAGNOSTICS, THERAPEUTICS,
AND SCREENING BASED ON THIS PROTEIN**

The research leading to this invention was supported in part by National Institutes of Health grant no. CA 67938 and National Institutes of Health Cancer Center Core grant no. CA 21765.

FIELD OF THE INVENTION

The present invention relates to identification of tumor suppressor activity of a protein, and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter.

BACKGROUND OF THE INVENTION

The cysteine proteases caspase-8 (alternatively named FLICE1/MACH1), caspase 9 (alternatively named Apaf 3/Mch6) and caspase-10 (alternatively named FLICE2/MACH 2) are related proteins that share homology with the prototypic member of the larger caspase gene family, interleukin-1 β -converting enzyme (ICE)/caspase 1 (Muzio *et al.*, J. Biol. Chem., 1998, 273:2926-2930; Boldin *et al.*, Cell, 1996, 85:803-815; Srinivasula *et al.*, J. Biol. Chem., 1996, 271:27099-27106; Orth *et al.*, J. Biol. Chem., 1996, 271:20977-20980; Scaffidi *et al.*, EMBO J.,

65031-230450

1998, 17:1675-1687; Vincenz *et al.*, J. Biol. Chem., 1997, 272:6578-6583; and Schulz *et al.*, 1994, Cell, 76:145-155). At least thirteen caspases have been identified thus far, and they are responsible for the proteolytic cascade that is essential for some aspects of apoptosis, including membrane blebbing and DNA degradation (Cryns *et al.*, Genes and Devel., 1998, 12:1551-1570).

5 Caspases 8, 9, and 10 are the only known members of this family that contain duplicated death effector domains (DEDs) in a long pro-domain in their amino terminus that precedes the cysteine protease catalytic domain in their carboxyl terminus. The DEDs allow caspase-8 to interact directly with an adaptor molecule, FADD, that also contains a DED. FADD, in turn, contains a death domain (DD) that allows it to directly associate with a number of cell death receptors (*e.g.*,
10 Fas, DR3).

Caspase-8, along with the adapter molecule FADD, is part of the death inducing signaling complex (DISC) associated with the Fas receptor (Medema, *et al.*, EMBO J., 1997, 16:2794-2804). It is activated by autoproteolytic cleavage following recruitment to the receptor through its interaction with the DED of FADD, which allows caspase-8 to form aggregates (Scaffidi *et al.*, EMBO J., 1998, 17:1675-1687; Yang *et al.*, Molecular Cell, 1998, 1:319-325; Muzio *et al.*, *supra*, 1998). These laboratories have shown that this oligomerization plays an important role in initiating the proper processing of the caspase itself, ultimately leading to an active caspase enzyme. Similarly, the DEDs of caspase 9 allow it to be recruited to a complex with Apafs 1 and 2, where its oligomerization leads to autocatalytic activation as well (Liu *et al.*,
20 Cell, 1997, 89:175-184; Srinivasula *et al.*, *supra*, 1998). Thus, caspases 8 and 9 are located upstream of all other caspases and their effector function is responsible for the activation of the "caspase cascade", and subsequent cell death, that occurs following Fas/DR3/TNFR1 activation and release of cytochrome c from mitochondria. Such important apoptotic signaling molecules may be likely targets for dysregulation/alteration during tumorigenesis.

SUMMARY OF THE INVENTION

25 The present invention relates to the discovery that *CASP8* is inactivated in cancers, and plays a role of a tumor suppressor gene. Thus, the invention provides a method for detecting inactivation of a *CASP8* gene. In particular, the method comprises detecting a

modification of genomic DNA comprising the *CASP8* gene, particularly the promoter, wherein such a modification results in inactivation of a *CASP8* gene. This method is particularly useful for obtaining a diagnosis or prognosis of a cancer, particularly a neuroblastoma.

Thus, the invention further provides a method for diagnosis or prognosis of a cancer, particularly one associated with amplification of a *MYC* oncogene, comprising detecting inactivation of a *CASP8* gene. According to the invention, inactivation of the *CASP8* gene is indicative of the presence of a cancer or a poor prognosis for outcome of treatment of the cancer, at least by conventional therapies. In a preferred embodiment, detection of inactivation of *CASP8* involves detecting methylation of the *CASP8* promoter.

The invention further provides a nucleic acid comprising at least a part of the genomic gene encoding *CASP8*. In particular, the nucleic acid is

- a *CASP8* genomic DNA;
- a *CASP8* promoter;
- a nucleic acid amplified by primers that correspond to a sequence selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28;
- a *CASP8* exon;
- a *CASP8* intron;
- or a nucleic acid having at least 15 bases and hybridizable under stringent conditions to a *CASP8* non-coding sequence.

In specific embodiments, the *CASP8* genomic DNA comprises a nucleic acid sequence as depicted in SEQ ID NOS:3-10, and the *CASP8* promoter comprises a nucleic acid sequence as depicted in SEQ ID NOS:1-2.

Furthermore, the invention provides a kit for detecting inactivation of a *CASP8* gene comprising a detection assay, *e.g.*, an immunoassay, PCR-based assay, or hybridization assay, for inactivation of a *CASP8* gene. Preferably, a kit of the invention provides for detection of the methylation of the *CASP8* promoter.

Having identified that inactivation of *CASP8* plays a role in cancer, the invention provides a method of treating a cancer in a subject. The method comprises administering an

amount of a vector that expresses a gene encoding functional CASP8 effective to express a functional level of CASP8 into cells of the subject, *i.e.*, gene therapy.

Accordingly, the invention provides a vector, such as a defective virus (particularly a neurotrophic virus) or non-viral vector, that expresses a gene encoding functional human CASP8 in human target cells.

The method further comprises using such gene therapy in combination with other anti-cancer therapies. Having identified that CASP8 overexpression sensitizes cancer cells to doxorubicin-induced apoptosis, the invention preferably comprises using such gene therapy in combination with chemotherapy.

In addition to gene therapy, recognition of the role of inactivation of the *CASP8* gene in cancer has led to discovery of a method of screening for a candidate compound that induces death-receptor-mediated apoptosis in cells where a *CASP8* gene is inactivated. This method comprises contacting cells in which a *CASP8* gene is inactivated with a candidate compound and detecting whether the cell undergoes apoptosis. An associated kit for screening for a candidate compound that induces death-receptor-mediated apoptosis in cells where a *CASP8* gene is inactivated, comprising cells in which a *CASP8* gene is inactivated and a detection assay for whether the cell undergoes apoptosis, is also provided.

The present invention will be better understood by reference to the Drawings, Detailed Description, and Examples, which follow.

DESCRIPTION OF THE DRAWINGS

Figure 1. Organization of the human *CASP8* gene relative to the domain structure of the corresponding protein. **TOP:** The BAC-43 and BAC-44 clones, relative to the genomic segment containing *CASP8*, are shown. Five different *CASP8* alternative splice products are also indicated above the gene, and they are designated according to Boldin *et al.* (Cell 85:803, 1996). **CENTER:** *CASP8* gene organization. Vertical black bars delineate the coding exons, which are numbered sequentially with their size given in bp. The lines between the vertical black bars denote introns. *CASP10* is shown upstream of *CASP8*. **BOTTOM:** Schematic of the caspase-8 domain structure compared to the organization of the gene shown

above. Salient features to the protein, *e.g.*, DEDs, caspase subunits, Asp-X cleavage sites (D-S and D-F), the catalytic cysteine residue (QACXG) (SEQ ID NO:11), and the substrate specificity motif (RNPAEGTW) (SEQ ID NO:12) are also shown.

Figures 2A and 2B. Southern blot analysis of total genomic DNA from three different neuroblastoma cell lines. Genomic DNA was subjected to restriction endonuclease digestion with either *EcoRI* or *HindIII* and then hybridized with the caspase-8 cDNA. This analysis revealed that both enzymes are associated with RFLPs. The arrows to the right of each panel indicate the different polymorphic fragments that hybridized with the cDNA probe. **A:** With *EcoRI*, an approximately 4.7 kb fragment loses an *EcoRI* site, generating an 8.8 kb fragment. **B:** With *HindIII*, a 4.0 kb fragment loses a *HindIII* restriction site, resulting in a new 7.2 kb fragment. The haplotype of the three cell lines for each of the enzymes is indicated below each panel. Size of genomic DNA in kb is indicated to the left of each panel.

Figures 3A, 3B, 3C, and 3D. Fluorescent *in situ* hybridization (FISH) localization of the human BAC clone containing *CASP8*. **A:** FISH on metaphase chromosome spreads with the human genomic BAC clone *CASP8.43* labeled with digoxigenin-11-UTP which is visualized with fluorescein-conjugated avidin (green; denoted by the arrows), and the human genomic chromosome 2 centromeric probe labeled with biotin-14-dATP which is visualized with Texas red Avidin (red; denoted by the arrowheads) (color photograph). For comparison, the chromosomes were visualized with DAPI counter staining. An interphase nucleus is also shown to demonstrate that the gene is single copy. **B:** Ideogram of G-banded human chromosome 2 indicating the location of *CASP8* (2q33-34). **C, D:** Fiber FISH analysis of the deletion in one of the NB7 alleles (**C**) and in the EBV-transformed B-cell containing a normal *CASP8* allele (**D**). A P1 clone containing only *CASP10* (green) was used as a reference for measurements to compare the length of the *CASP8* P1 hybridization signal (red) from NB7 with a EBV-transformed B-cell (the *CASP8* P1 does not contain *CASP10*). The approximate size of the deletion is indicated.

Figures 4A, 4B, 4C, 4D, and 4E. Analysis of *CASP8* structure and expression in human neuroblastoma cell lines. Heterozygous (+/-) deletions determined by FISH are indicated above the appropriate cell line. **A:** Southern blot analysis of the human *CASP8* locus. The variant 8.0 and 4.8 kb *EcoRI* fragments of *CASP8* are polymorphisms. **B:** Southern blot analysis

of the human *CASP10* locus in the same NB cell lines. **C:** Northern blot analysis of caspase-8 mRNA expression in the same NB cell lines. **D:** Western blot analysis of the caspase-8 and caspase-10 proteins in the various neuroblastoma cell lines from SJCRH (NB1-NB21), Memorial Sloan Kettering (SK), and small-cell lung carcinoma cell lines (NCIH). The blot includes tubulin control for the protein loading quantification. **E:** Immunoblot analysis of N-Myc expression in the NB cell lines.

Figure 5. RNase protection analysis of the expression of apoptotic genes in human neuroblastoma cell lines.

Figures 6A and 6B. Methylation status of *CASP8*, and its effect on caspase-8 expression, in NB cell lines. **A:** 5-aza-cytidine treatment of NB10 and NB14 results in the expression of caspase-8. **B:** Methylation PCR analysis of the NB cell lines. The methylated primers detect only DNA that contain methylated CpG dinucleotides, whereas the unmethylated primers detect only DNA that contains no methylated CpG dinucleotides.

Figures 7A, 7B, and 7C. Analysis of neuroblastoma patient material by methylation PCR and FISH. **A:** Patient samples SJ-890191 and SJ-870015 generate a PCR product corresponding to methylated *CASP8* alleles and little if any product using the unmethylated oligonucleotide set. Conversely, SJ-910008 generates a PCR product corresponding to unmethylated *CASP8* alleles and little if any PCR product corresponding to methylated alleles. The other NB patient samples, SJ-890175 and SJ-920017, appear to contain both methylated and unmethylated *CASP8* alleles. The NB12 (positive for methylated *CASP8* alleles, negative for unmethylated alleles) and HeLa (positive for unmethylated *CASP8* alleles, negative for methylated alleles) were used as controls. **B, C:** Semi-quantitative PCR analysis of SJ-910008 and SJ-890191 patient material for caspase-8 (**B**) and caspase-9 (**C**) mRNAs. The presence (+) or absence (-) of reverse transcriptase in the respective reactions is shown above each gel.

Figures 8A, 8B, 8C, 8D, and 8E. Effects of retrovirus expression of caspase-8 in three different NB cell lines that are caspase-8 nulls. **A:** Immunoblot demonstrating that caspase-8 (wild type) and caspase-8(DN) are expressed. The caspase-8(DN) product migrates at a higher molecular weight due to an HA-tag attached to its carboxyl-terminus. **B, C:** Morphology of

NB7/Casp8 cells 5 hours after treatment with TNF α and cycloheximide. Membrane blebbing (Nomarski view, **B**) and condensed chromatin (visualized by DAPI staining, **C**), characteristics of apoptotic cells, are clearly visible. **D**: Percentage of cells that are positive for cell surface annexin-V staining, another hallmark of apoptotic cells. The various cell lines and their treatment regimens are shown at the bottom. **E**: Apoptotic induction by Fas mAb in proliferating NB8 and NB10 cells stably expressing caspase-8 at a low level. Induction measured as percentage of cells that are TUNEL-positive. The various cell lines and their treatment regimens are shown at the bottom.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, on the surprising discovery that *CASP8* is functionally inactivated in greater than 90% of all *MYCN* amplified neuroblastoma cell lines analyzed. Neuroblastoma is a pediatric solid tumor, and those cases with *MYCN* amplification have a particularly poor prognosis. Inactivation of *CASP8* was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. The data further show that the *CASP10* gene, which is closely linked to *CASP8*, is not affected in a cell line containing the homozygous deletion. This discovery is significant in oncology, because cells in which caspase-8 is not expressed are not capable of undergoing apoptosis mediated by death receptors such as Fas and DR3. Furthermore, when caspase-8 expression is re-established in cell lines, either by microinjection or 5-aza-cytidine treatment, the cells undergo apoptosis. These data link caspases directly to tumorigenesis and suggest that *CASP8* is a tumor suppressor, the first such gene identified in neuroblastoma.

Initial data also showed that inactivation of caspase-8 is prevalent in a subset of small-cell lung cancers. This type of cancer is associated with an amplified *LMYC* oncogene. It is likely that *CASP8* is inactivated in other tumors as well, particularly when there is overexpression or amplification of *MYC* genes. Members of the *MYC* gene family include *NMYC*, *LMYC*, *cMYC*, etc.

The *CASP8* promoter region sequences, in particular Region 1 (SEQ ID NO:1)

and Region 2 (SEQ ID NO:2), which have not been previously characterized, are crucial to the design and execution of the genomic methylation PCR analysis of *CASP8* gene inactivation.

Methylation PCR can be used to examine even minute amounts of patient material to demonstrate whether the *CASP8* gene expresses an mRNA and protein product. This method, and associated kits, are particularly preferred for evaluating *CASP8* inactivation. In a specific embodiment, methylation PCR analysis can be performed with the primers of SEQ ID NOS:29-34, as described in the Examples, *infra*. The promoter Region 1 sequence is located upstream (5') to exon 1, which is the alternatively-spliced 5' untranslated region that is less commonly used. The promoter Region 2 sequence is located downstream (3') of exon 1 and upstream of exon 2, which is the more commonly used 5' untranslated region.

As used herein, "inactivation of caspase-8" and "inactivation of *CASP8* gene" are used interchangeably to refer to a modification of the genomic sequence of *CASP8* that results in impairment of transcription or translation of the gene, or of activity of the gene product. For example, genomic methylation of the *CASP8* promoter results in inactivation of that allele. Similarly, deletion of the segment of the chromosome containing *CASP8*, *i.e.*, deletion of the *CASP8* gene, results in inactivation of that allele of the gene. Inactivation of one allele may reduce the level of expression of caspase-8 to below that necessary for proper cellular regulation. No caspase-8 expression occurs with inactivation of both alleles by either or both mechanisms (or any of the other mechanisms discussed herein).

In addition to genomic methylation of the promoter and gene deletion, the term "modification of genomic DNA" refers to any mutation of the DNA that impairs gene expression or protein activity. For example, mutations that lead to insertion of a heterologous sequence in the gene, truncation of the gene, and introduction of a nonsense mutation, a frameshift mutation, a splice-site mutation, or a missense mutation can result in inactivation of the gene. Furthermore, point mutations (polymorphisms) can impact mRNA stability and translation efficiency, for example by introducing a base that affects secondary structure of the message. Other point mutations, for example in the caspase DED or catalytic domains, can lead to expression of an inactive protein. In the latter circumstance, protein expression may be detectable (*e.g.*, by immunoassay), so only analysis of the *CASP8* gene permits identification of an inactivating point

mutation.

Cancers related to the present invention include solid tumors, including carcinomas, and non-solid tumors, including hematologic malignancies. Preferably, these tumors overexpress or evidence amplification of a *MYC* family gene. More preferably, caspase-8 is inactivated in these tumors. Examples of solid tumors according to the invention include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma. Hematologic malignancies include leukemias, lymphomas, and multiple myelomas. The following are non-limiting preferred examples of the cancers that can be diagnosed (including determination of a diagnosis or prognosis, or both) or treated in accordance with the present invention: neuroblastoma (particularly juvenile neuroblastoma), small-cell lung carcinoma, non-small-cell lung carcinoma, colorectal carcinoma, and uterine cervical carcinoma.

The invention advantageously involves the identification and characterization of the genomic sequence of *CASP8* (SEQ ID NOS:3-10). The results show that the *CASP8* gene contains at least 11 exons spanning approximately 30 kb on human chromosome band 2q33-34. This region of human chromosome 2 was previously reported as the location of the *CASP10* gene, whose product is closely related to caspase-8. Chromosome 2 band q33-34 is also involved in tumorigenesis, with loss of heterogeneity (LOH) being reported in a number of tumors. The invention further results from identification of diagnostic restriction fragment polymorphisms;

*Eco*RI and *Hind*III polymorphisms were discovered that may prove to be useful in disease analysis.

The specific following genomic sequences of *CASP8* are provided:

exon 3, flanked by partial sequences of introns 2 and 3	SEQ ID NO:3
exon 4, flanked by partial sequences of introns 3 and 4	SEQ ID NO:4
exon 5, flanked by partial sequences of introns 4 and 5	SEQ ID NO:5
exon 6, flanked by partial sequences of introns 5 and 6	SEQ ID NO:6
exon 7, flanked by partial sequences of introns 6 and 7	SEQ ID NO:7
exon 8, flanked by partial sequences of introns 7 and 8	SEQ ID NO:8
exon 9, flanked by partial sequences of introns 8 and 9	SEQ ID NO:9
exon 10, flanked by partial sequences of introns 9 and 10	SEQ ID NO:10

Table 1, *infra*, identifies the intron-exon boundaries for these sequences. Caspase-8 is encoded by exons 3-10.

Abbreviations. The following abbreviations have been used: aa, amino acids; bp, base pairs; cDNA, DNA complementary to RNA; DD, death domain, DED, death effector domain; DISC, death-inducing signaling complex; FADD, Fas associated death domain; FISH, fluorescent *in situ* hybridization; ICE, interleukin-1 β -converting enzyme; GFP, green fluorescent protein; kb(s), kilobase or 1000 bp; nt, nucleotide; oligo, oligodeoxyribonucleotide; ORF, open reading frame; RFLP, restriction fragment length polymorphism; SSC, 0.15M NaCl/0.015M Na, citrate pH7.6; UTR, untranslated region(s).

General Definitions

In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range.

Alternatively, particularly with respect to biological systems or processes, the term means within an order of magnitude, and preferably a factor of two, of a value.

As used herein, the term "isolated" means that the referenced material is free of components present in the natural environment in which the material is normally found. In particular, isolated biological material is free of cellular components. In the case of nucleic acid

molecules, an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment. In another embodiment, an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome. In yet another embodiment, the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules can be inserted into plasmids, cosmids, artificial chromosomes, and the like. Thus, in a specific embodiment, a recombinant nucleic acid is an isolated nucleic acid. An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane-associated protein. An isolated organelle, cell, or tissue is removed from the anatomical site in which it is found in an organism. An isolated material may be, but need not be, purified.

The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, *i.e.*, contaminants. For example, a purified protein is preferably substantially free of other proteins or nucleic acids with which it is associated in a cell; a purified nucleic acid molecule is preferably substantially free of proteins or other unrelated nucleic acid molecules with which it can be found within a cell. A purified tumor cell is preferably substantially free of other normal cells. As used herein, the term "substantially free" is used operationally, in the context of analytical testing of the material. Preferably, purified material substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.

The use of italics indicates a nucleic acid molecule (*e.g.*, *CASP8*, cDNA, gene, etc.); normal text (*e.g.*, CASP8 or caspase-8) indicates the polypeptide or protein.

CASP8 Nucleic Acids

The present invention contemplates isolation of a nucleic acids encoding a CASP8 of the invention, including a full length, or naturally occurring form of CASP8, and any antigenic

fragments thereof from any source. Other nucleic acids encode all or part of a *CASP8* exon or intron, or both. In a specific embodiment, the invention provides a complete and partial *CASP8* genomic DNAs (SEQ ID NOS:3-10). In specific embodiments, clones BAC-43 (also termed herein CASP-43) and BAC-44 (also termed herein CASP-44), or clones having similar structure, contain the complete *CASP8* genomic gene. The invention also provides *CASP8* restriction fragments and restriction fragment polymorphisms, including, but by no means limited to, *EcoRI* fragments of 4.7 kb and about 8.0 kb, and *HindIII* fragments of 4.0 kb and about 7.2 kb. Polymorphic variants of *CASP8*, particularly polymorphisms (*i.e.*, mutations) that result in inactivation of caspase-8, are also included. Furthermore, although the present invention relates to human *CASP8* nucleic acids, including allelic variants (*e.g.*, as represented by the RFLPs noted above), in certain embodiments, such as for gene therapy, non-human variants of *CASP8* are contemplated.

In a further embodiment, the invention provides Regions 1 (SEQ ID NO:1) and 2 (SEQ ID NO:2) of the *CASP8* promoter. Considered from the 5' to 3' direction, these two regions flank exon 1 (a 5' UTR that is less commonly used), and exons 1 and 2 (the alternatively spliced 5' UTR that is more commonly used) flank promoter Region 2. Also provided are oligonucleotides that hybridize to the promoters, and particularly to methylated or unmethylated forms of the promoters. In a specific embodiment, these oligonucleotides are PCR primer pairs having sequences as depicted in SEQ ID NOS:29-34, as described in Example 3, *infra*.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature, *e.g.*, in Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition, 1989, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (herein "Sambrook *et al.*, 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II, D.N. Glover ed., 1985; *Oligonucleotide Synthesis*, M.J. Gait ed., 1984; *Nucleic Acid Hybridization*, B.D. Hames and S.J. Higgins eds., 1985; *Transcription And Translation*, B.D. Hames and S.J. Higgins eds., 1984; *Animal Cell Culture*, R.I. Freshney ed., 1986; *Immobilized Cells And Enzymes*, IRL Press, 1986; B. Perbal, *A Practical Guide To Molecular Cloning*, 1984; *Current Protocols in Molecular Biology*, F.M.

Ausubel *et al.* eds., John Wiley and Sons, Inc., 1994.

Therefore, if appearing herein, the following terms shall have the definitions set out below.

A "vector" is a recombinant nucleic acid construct, such as plasmid, phage genome, virus genome, cosmid, or artificial chromosome, to which another DNA segment may be attached. In a specific embodiment, the vector may bring about the replication of the attached segment, *e.g.*, in the case of a cloning vector. A "replicon" is any genetic element (*e.g.*, plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, *i.e.*, it is capable of replication under its own control. The term "vector" includes both viral and nonviral means for introducing the nucleic acid into a cell *in vitro*, *ex vivo* or *in vivo*. Non-viral vectors include plasmids, liposomes, electrically charged lipids (cytofectins), DNA-protein complexes, and biopolymers. Viral vectors include retrovirus, adeno-associated virus, pox, baculovirus, vaccinia, herpes simplex, Epstein-Barr and adenovirus vectors, as set forth in greater detail below. In addition to a nucleic acid according to the invention, a vector may also contain one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.).

A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. A cell has been "transformed" by exogenous or heterologous DNA when the transfected DNA is expressed and effects a function or phenotype on the cell in which it is expressed.

The term "heterologous" refers to a combination of elements not naturally occurring. For example, heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. A heterologous expression regulatory element is a such an element operatively associated with a different gene than the one it is operatively associated with in nature, such as a CMV promoter operatively associated with a *CASP8* coding region. In the

context of the present invention, an *CASP8* gene is heterologous to vector DNA in which it is inserted for cloning or expression.

A "nucleic acid molecule" (or alternatively "nucleic acid") refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear (*e.g.*, restriction fragments) or circular DNA molecules, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

The present invention provides antisense nucleic acids (including ribozymes), which may be used as probes or to inhibit expression of *CASP8*. An "antisense nucleic acid" is a single stranded nucleic acid molecule which, on hybridizing with complementary bases in an RNA or DNA molecule, inhibits the latter's role. If the RNA is a messenger RNA transcript, the antisense nucleic acid is a countertranscript or mRNA-interfering complementary nucleic acid. As presently used, "antisense" broadly includes RNA-RNA interactions, RNA-DNA interactions, ribozymes, and RNase-H mediated arrest. Antisense nucleic acid molecules can be encoded by a recombinant gene for expression in a cell (*e.g.*, U.S. Patent Nos. 5,814,500 and 5,811,234), or alternatively they can be prepared synthetically (*e.g.*, U.S. Patent No. 5,780,607).

Specific examples of synthetic oligonucleotides envisioned for this invention include oligonucleotides that contain phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl, or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are those with $\text{CH}_2\text{-NH-O-CH}_2$, $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$, $\text{CH}_2\text{-O-}$

N(CH₃)-CH₂, CH₂-N(CH₃)-N(CH₃)-CH₂ and O-N(CH₃)-CH₂-CH₂ backbones (where phosphodiester is O-PO₂-O-CH₂). US Patent No. 5,677,437 describes heteroaromatic oligonucleoside linkages. Nitrogen linkers or groups containing nitrogen can also be used to prepare oligonucleotide mimics (U.S. Patents Nos. 5,792,844 and 5,783,682). US Patent No. 5,637,684 describes phosphoramidate and phosphorothioamidate oligomeric compounds. Also envisioned are oligonucleotides having morpholino backbone structures (U.S. Pat. No. 5,034,506). In other embodiments, such as the peptide-nucleic acid (PNA) backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone (Nielsen *et al.*, Science, 1991, 254:1497). Other synthetic oligonucleotides may contain substituted sugar moieties comprising one of the following at the 2' position: OH, SH, SCH₃, F, OCN, O(CH₂)_nNH₂ or O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O-; S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted sialyl; a fluorescein moiety; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. Oligonucleotides may also have sugar mimetics such as cyclobutyls or other carbocyclics in place of the pentofuranosyl group. Nucleotide units having nucleosides other than adenosine, cytidine, guanosine, thymidine and uridine may be used, such as inosine.

A "gene" is used herein to refer to a portion of a DNA molecule that includes a polypeptide coding sequence operatively associated with expression control sequences. Thus, a gene includes both transcribed and untranscribed regions. The transcribed region may include introns, which are spliced out of the mRNA, and 5'- and 3'-untranslated (UTR) sequences along with protein coding sequences. In one embodiment, a gene can be a genomic or partial genomic sequence, in that it contains one or more introns. In another embodiment, the term gene may refer to a cDNA molecule (*i.e.*, the coding sequence lacking introns).

A DNA "coding sequence" is a double-stranded DNA sequence which is

transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus.

5 "Expression control sequences", *e.g.*, transcriptional and translational control sequences, are regulatory sequences that flank a coding sequence, such as promoters, enhancers, suppressors, terminators, and the like, and that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence. On mRNA, a ribosome binding site is an
10 expression control sequence.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control" of transcriptional and translational
20 control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced (if it contains introns) and translated into the protein encoded by the coding sequence.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule
25 can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (*see* Sambrook *et al.*, 1989). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a T_m of 55°C, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30% formamide,

5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher T_m , e.g., 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest T_m , e.g., 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook *et al.*, 1989, 9.50-9.51). For hybridization with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (see Sambrook *et al.*, 1989, 11.7-11.8). A minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; preferably at least about 15 nucleotides; and more preferably the length is at least about 20 nucleotides.

In a specific embodiment, the term "standard hybridization conditions" refers to a T_m of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the T_m is 60°C; in a more preferred embodiment, the T_m is 65°C. In a specific embodiment, "high stringency" refers to hybridization and/or washing conditions at 68°C in 0.2XSSC, at 42°C in 50% formamide, 4XSSC, or under conditions that afford levels of hybridization equivalent to those observed under either of these two conditions.

As used herein, the term "oligonucleotide" refers to a nucleic acid, generally of at least 10, preferably at least 15, and more preferably at least 20 nucleotides, that is hybridizable to a genomic DNA molecule, a cDNA molecule, or an mRNA molecule encoding a gene, mRNA, cDNA, or other nucleic acid of interest. Oligonucleotides can be labeled, e.g., with ^{32}P -nucleotides or nucleotides to which a ligand molecule, such as biotin, has been covalently conjugated. In one embodiment, a labeled oligonucleotide can be used as a probe to detect the presence of a nucleic acid. In another embodiment, oligonucleotides (one or both of which may

be labeled) can be used as PCR or sequencing primers, either for cloning full length or a fragment of CASP8, or to detect the presence of nucleic acids encoding CASP8. In a further embodiment, an oligonucleotide of the invention can form a triple helix with a CASP8 DNA molecule. In still another embodiment, a library of oligonucleotides arranged on a solid support, such as a silicon wafer or chip, can be used to detect various CASP8 polymorphisms of interest. Generally, oligonucleotides are prepared synthetically, preferably on a nucleic acid synthesizer. Accordingly, oligonucleotides can be prepared with non-naturally occurring phosphoester analog bonds, such as thioester bonds, etc.

As used herein, the term "homologous" in all its grammatical forms and spelling variations refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck *et al.*, Cell, 1987, 50:667). Such proteins (and their encoding genes) have sequence homology, as reflected by their high degree of sequence similarity.

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that may or may not share a common evolutionary origin (*see* Reeck *et al.*, *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb such as "highly," may refer to sequence similarity and may or may not relate to a common evolutionary origin.

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least about 30%, and preferably at least about 50%, of the nucleotides match over the defined length of the DNA sequences. An example of such a sequence is an allelic variant of the specific CASP8 genes of the invention. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks or from commercial sources (BLAST, DNA Strider, DNA Star, FASTA, etc.) using standard or default parameters, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. *See, e.g.*, Sambrook *et al.*,

1989; *DNA Cloning*, Vols. I & II, *supra*; *Nucleic Acid Hybridization*, *supra*.

Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than about 80%, preferably greater than about 90%, of the amino acids are identical, or greater than about 85%, preferably greater than about 95%, are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, *Version 7*, Madison, Wisconsin) pileup program, or any of the sequence alignment programs described above.

A gene encoding CASP8, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library. Methods for obtaining *CASP8* gene are well known in the art, as described above (*see, e.g.,* Sambrook *et al.*, 1989). The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.,* a DNA "library"), and preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein (*e.g.,* a peripheral blood leukocyte cell library, since these are the cells that evidence high levels of expression of CASP8), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (*see, e.g.,* Sambrook *et al.*, 1989; *DNA cloning, supra*). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene. Identification of the specific DNA fragment containing the desired *CASP8* gene may be accomplished in a number of ways. For example, a portion of a *CASP8* gene exemplified *infra* can be purified and labeled to prepare a labeled probe, and the generated DNA may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, *Science*, 1977, 196:180; Grunstein and Hogness, *Proc. Natl. Acad. Sci. USA*, 1975, 72:3961). Those DNA fragments with substantial homology to the probe, such as an allelic variant from another individual, will hybridize. In a specific embodiment, highest stringency hybridization conditions are used to identify a homologous *CASP8* gene.

Further selection can be carried out on the basis of the properties of the gene, *e.g.,* if the gene encodes a protein product having the isoelectric, electrophoretic, amino acid

composition, partial or complete amino acid sequence, antibody binding activity, or ligand binding profile of CASP8 protein as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, immunological, or functional properties of its expressed product.

5 The present invention also relates to cloning vectors containing genes encoding analogs and derivatives of CASP8 of the invention, that have the same or homologous functional activity as CASP8. The production and use of derivatives and analogs related to CASP8 are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with a
10 full-length, wild-type CASP8 of the invention. Such functions include FADD and death receptor binding, induction of apoptosis, autoproteolytic cleavage, and aggregate formation. Chimeric fusion proteins with CASP8, such as GST or HIS-tagged CASP8, are contemplated, as are fusion proteins that contain functional domains (discussed below).

CASP8 derivatives can be made by altering encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity relative to native CASP8. For example, chimeric derivatives with a greater self-aggregation potential, *e.g.*, prepared by incorporating an additional or stronger aggregation sequence, may have increased functional activity. Alternatively, a chimeric CASP8 protein that contains the FADD death
20 domain may be especially effective for generation of a death-inducing signaling complex, even in the absence of FADD.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a *CASP8* gene may be used in the practice of the present invention. These include but are not limited to allelic genes and
25 nucleotide sequences comprising all or portions of *CASP8* genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, the CASP8 derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a CASP8 protein including altered sequences in which functionally equivalent

amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity and, if present, charge, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point. Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free CONH₂ can be maintained.

The genes encoding CASP8 derivatives and analogs of the invention can be produced by various methods known in the art. The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of CASP8, care should be taken to ensure that the modified gene remains within the same translational reading frame as the *CASP8* gene, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the CASP8-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis

(Hutchinson, C., *et al.*, J. Biol. Chem., 1978, 253:6551; Zoller and Smith, DNA, 1984, 3:479-488; Oliphant *et al.*, Gene, 1986, 44:177; Hutchinson *et al.*, Proc. Natl. Acad. Sci. USA, 1986, 83:710), use of TAB linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (*see* Higuchi, in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich ed., Stockton Press, 1989, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, *E. coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, *e.g.*, pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences.

Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle vector plasmid, which provides for expansion in a cloning cell, *e.g.*, *E. coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *E. coli* and *Saccharomyces cerevisiae* by linking sequences from an *E. coli* plasmid with sequences from the yeast 2 μ plasmid.

CASP8 Polypeptides

The nucleotide sequence coding for CASP8, including derivatives or analogs

thereof, or a functionally active chimeric protein thereof (herein collectively "caspase-8" or "CASP8"), can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence *in vivo*. Thus, the nucleic acid encoding CASP8 of the invention is operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences. An expression vector also preferably includes a replication origin.

Alternatively, an CASP8 polypeptide of the invention can be prepared using well-known techniques in peptide synthesis, including solid phase synthesis (using, *e.g.*, BOC or Fmoc chemistry), or peptide condensation techniques.

As used herein, the terms "polypeptide" and "protein" may be used interchangeably to refer to the gene product (or corresponding synthetic product) of a *CASP8* gene. The term "protein" may also refer specifically to the polypeptide as expressed in cells. A peptide is generally a fragment of a polypeptide, *e.g.*, of about six or more amino acid residues.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding CASP8 and/or its flanking regions. Preferably, such control sequences, whether a promoter or enhancer, or both, permit high level expression of caspase-8 in the target cell, particularly for gene therapy (described *infra*).

Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, adeno-associated virus, herpes virus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

A recombinant CASP8 protein of the invention, or functional fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally, after integration of the coding sequence by recombination. In this regard, any of a number of

amplification systems may be used to achieve high levels of stable gene expression (See Sambrook *et al.*, 1989).

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

Expression of CASP8 protein may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. In one embodiment, the promoter permits high level expression in a mammalian, and more preferably human, host cell. For example, viral promoters, some of which are listed below, often permit high level expression. Other such promoters are known. Promoters which may be used to control CASP8 gene expression include, but are not limited to, cytomegalovirus (CMV) promoter (U.S. Patent Nos. 5,168,062 and 5,385,839), the SV40 early promoter region (Benoist and Chambon, *Nature*, 1981, 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, *et al.*, *Cell*, 1980, 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. USA*, 1981, 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster *et al.*, *Nature*, 1982, 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, *et al.*, *Proc. Natl. Acad. Sci. USA*, 1978, 75:3727-3731), or the *tac* promoter (DeBoer, *et al.*, *Proc. Natl. Acad. Sci. USA*, 1983, 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, *Cell*, 1984, 38:639-646; Ornitz *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 1986, 50:399-409; MacDonald, *Hepatology*, 1987, 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, *Nature*, 1985, 315:115-122), immunoglobulin gene control region which is active in lymphoid cells

(Grosschedl *et al.*, Cell, 1984, 38:647-658; Adames *et al.*, Nature, 1985, 318:533-538; Alexander *et al.*, Mol. Cell. Biol., 1987, 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, Cell, 1986, 45:485-495), albumin gene control region which is active in liver (Pinkert *et al.*, Genes and Devel., 1987, 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, Mol. Cell. Biol., 1985, 5:1639-1648; Hammer *et al.*, Science, 1987, 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, Genes and Devel., 1987, 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram *et al.*, Nature, 1985, 315:338-340; Kollias *et al.*, Cell, 1986, 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, Cell, 1987, 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, Nature, 1985, 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, Science, 1986, 234:1372-1378). Other promoters useful for practice of this invention are ubiquitous promoters (*e.g.*, HPRT, vimentin, actin, tubulin), intermediate filament promoters (*e.g.*, desmin, neurofilaments, keratin, GFAP), therapeutic gene promoters (*e.g.*, MDR type, CFTR, factor VIII), tissue-specific promoters (*e.g.*, actin promoter in smooth muscle cells), promoters which are preferentially activated in dividing cells, promoters which respond to a stimulus (*e.g.*, steroid hormone receptor, retinoic acid receptor), tetracycline-regulated transcriptional modulators, retroviral LTR, metallothionein, E1a, and MLP promoters. Tetracycline-regulated transcriptional modulators are described in PCT Publication No. WO 96/01313.

In a specific embodiment, promoters specific for expression in cells of the CNS can be used, *e.g.*, for gene therapy of neuroblastoma or another CNS tumor. For example, the promoters for the human tyrosine hydroxylase gene (Kim *et al.*, Nucl. Acids Res., 1998, 26:1793-800), human dopamine beta-hydroxylase (DBH) gene (Zellmer *et al.*, J. of Neurosci., 1995, 15:8109-20) and human ENC-1 gene (Hernandez *et al.*, Exp. Cell Res., 1998, 242:470-7) are CNS-specific.

Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran,

calcium phosphate precipitation, lipofection (liposome fusion), use of a gene gun, or a DNA vector transporter (*see, e.g.*, Wu *et al.*, J. Biol. Chem., 1992, 267:963-967; Wu and Wu, J. Biol. Chem., 1988, 263:14621-14624; Canadian Patent Application No. 2,012,311).

5

Antibodies to CASP8

According to the invention, CASP8 polypeptides, whether produced recombinantly or by chemical synthesis or purified from cells that express the protein endogenously, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize the CASP8 polypeptide.

10

Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Such an antibody is specific for human CASP8.

15

Various procedures known in the art may be used for the production of polyclonal antibodies to CASP8 polypeptide or derivative or analog thereof. For the production of antibody, various host animals can be immunized by injection with the CASP8 polypeptide, or a derivative (*e.g.*, fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the CASP8 polypeptide or fragment thereof can be conjugated to an immunogenic carrier, *e.g.*, bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

20

25

For preparation of monoclonal antibodies directed toward the CASP8 polypeptide, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (Nature, 1975, 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, Immunology Today, 1983, 4:72; Cote *et al.*, Proc. Natl. Acad. Sci.

USA, 1983, 80:2026-2030), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985). Production of human antibodies by CDR grafting is described in U.S. Patent Nos. 5,585,089, 5,693,761, 5,693,762, and 5,225,539, and PCT Publication No. WO91/09967. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (PCT Publication No. WO 89/12690). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, J. Bacteriol., 1984, 159:870); Neuberger *et al.*, Nature, 1984, 312:604-608; Takeda *et al.*, Nature, 1985, 314:452-454) by splicing the genes from a mouse antibody molecule specific for an CASP8 polypeptide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent Nos. 5,476,786, 5,132,405, and 4,946,778) can be adapted to produce CASP8 polypeptide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse *et al.*, Science, 1989, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an CASP8 polypeptide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays,

immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of an CASP8 polypeptide, one may assay generated hybridomas for a product which binds to an CASP8 polypeptide fragment containing such epitope.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the CASP8 polypeptide, *e.g.*, for Western blotting, imaging CASP8 polypeptide *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques mentioned above or known in the art. Such antibodies may exhibit surprisingly superior properties in immunodiagnostic (or immunoprognostic) assays for CASP8.

Diagnostics

The present invention provides for evaluating cancer in a subject or patient based on detecting whether caspase-8 has been inactivated. This evaluation can provide either a diagnosis or a prognosis, or both. For example, detecting inactivation of caspase-8 in neuroblastoma provides a diagnosis of aggressive neuroblastoma, and a prognosis of a poor outcome from traditional therapies.

The term "diagnosis" in any grammatical form refers to the identification of a particular disease condition in a subject or patient. As the skilled physician knows, almost any diagnosis is based on a multiple of determinants, including symptomology, histology, and other criteria, which together form a diagnosis. Thus, when used herein, diagnosis according to the invention is one component or determinant of the final diagnosis. The term "prognosis" in any grammatical form refers to prediction of a disease outcome, *e.g.*, whether the subject suffering from the disease is likely to improve or regress.

Any form of cancer, *e.g.*, as discussed above, can be evaluated using the diagnostic methods of the invention. Preferably, the cancer is neuroblastoma (particularly

juvenile neuroblastoma), small-cell lung carcinoma, non-small-cell lung carcinoma, colorectal carcinoma, or uterine cervical carcinoma.

Various methods are known in the art for evaluating inactivation of caspase-8, either by nucleic acid based assays or protein based assays. These methods are discussed in greater detail below. In addition, the components useful in practicing the diagnostic and prognostic aspects of the invention can be conveniently provided in kit form, as set forth in greater detail below. Such kits contain, at least, a detection assay for inactivation of caspase-8.

Nucleic Acid Assays and Kits

Nucleic acid assays for inactivation of *CASP8* are based on detection of mutations or modifications in the *CASP8* gene that result in its inactivation. The DNA may be obtained from any cell source. Non-limiting examples of cell sources available in clinical practice include without limitation blood cells, buccal cells, cervicovaginal cells, epithelial cells from urine, fetal cells, or any cells present in tissue obtained by biopsy. Cells may also be obtained from body fluids, including without limitation blood, plasma, serum, lymph, milk, cerebrospinal fluid, saliva, sweat, urine, feces, and tissue exudates (e.g., pus) at a site of infection or inflammation. DNA is extracted from the cell source or body fluid using any of the numerous methods that are standard in the art. It will be understood that the particular method used to extract DNA will depend on the nature of the source. Generally, the minimum amount of DNA to be extracted for use in the present invention is about 25 pg (corresponding to about 5 cell equivalents of a genome size of 4×10^9 base pairs).

Modifications of the *CASP8* genomic DNA include genomic methylation of the promoter. In a preferred aspect of the invention, evaluation of inactivation of *CASP8* involves an assay for methylation of the *CASP8* promoter. It has been found that in most cases, inactivation of *CASP8* results from methylation of the promoter and not from gene deletion (see Examples 2, 3, *infra*). In a specific embodiment, methylation of the promoter can be detected by a methylation polymerase chain reaction (PCR) assay (see Belinsky *et al.*, Proc. Natl. Acad. Sci. USA, 1998, 95:11891; Merlo *et al.*, Nature Medicine, 1995, 1:686), preferably using primers designed based on the promoter regions depicted in SEQ ID NOS: 1 and 2. In a specific embodiment, primer

pairs can be used to detect methylated, bisulfite treated promoter DNA (*e.g.*, SEQ ID NOS:29 and 30), unmethylated, bisulfite-treated promoter DNA (*e.g.*, SEQ ID NOS:31 and 32), and wild-type (un-bisulfite treated) DNA (*e.g.*, SEQ ID NOS:33 and 34). A major advantage of this method is that it can be used to evaluate a small number of tumor cells isolated from patient tissue, even if they are contaminated with normal cells.

Mutations include an insertion in the gene, deletion of the gene, truncation of the gene (*e.g.*, due to a nonsense, missense, or frameshift mutation), or dysregulation of gene expression (*e.g.*, due to a frameshift mutation or a splice-site mutation). In a specific embodiment, *infra*, *CASP8* is heterozygously or homozygously deleted from chromosome 2.

Identification of gene deletion is readily accomplished using nucleic acid probes or PCR analysis. Determination of polymorphic positions is achieved by any means known in the art, including but not limited to direct sequencing, hybridization with allele-specific oligonucleotides, allele-specific PCR, ligase-PCR, HOT cleavage, denaturing gradient gel electrophoresis (DGGE), and single-stranded conformational polymorphism (SSCP). Direct sequencing may be accomplished by any method, including without limitation chemical sequencing, using the Maxam-Gilbert method; by enzymatic sequencing, using the Sanger method; mass spectrometry sequencing; and sequencing using a chip-based technology (see, *e.g.*, Little *et al.*, Genet. Anal., 1996, 6:151). Preferably, DNA from a subject is first subjected to amplification by polymerase chain reaction (PCR) using specific amplification primers.

Gene expression, or lack of gene expression, can be directly evaluated by detecting *CASP8* mRNA. Methods for detecting mRNA include Northern blotting and reverse transcriptase (RT)-PCR. These methods can be used to determine whether or not expression occurs, and whether a truncated (or oversized) message is expressed. All of these factors can help establish inactivation of caspase-8.

A nucleic acid assay kit of the invention will comprise a nucleic acid that specifically hybridizes under stringent conditions to a *CASP8* gene, and an assay detector, *e.g.*, a label. Where the kit is a PCR-based kit, a primer pair will be included; in this case, the detector may simply be a reagent such as ethidium bromide to quantify amplified DNA. In a preferred embodiment, a nucleic acid based kit of the invention includes primer pairs for PCR analysis of

CASP8 promoter methylation. In a more preferred embodiment, the kit contains primer pairs that can be used to detect methylated, bisulfite treated promoter DNA (*e.g.*, SEQ ID NOS:29 and 30), unmethylated, bisulfite-treated promoter DNA (*e.g.*, SEQ ID NOS:31 and 32), and wild-type (un-bisulfite treated) DNA (*e.g.*, SEQ ID NOS:33 and 34). Optional components include buffer or buffer reagents, nucleotides, and instructions for use of the kit. If possible, a positive control is also included, *e.g.*, a probe or primer pair for an endogenously expressed gene, such as actin or tubulin.

Protein Based Assays

As an alternative to analyzing *CASP8* nucleic acids, one can evaluate caspase-8 on the basis of protein expression. Indeed, this assay may be the most informative, since *CASP8* mRNA levels may appear high, but a mutation in the sequence may make the mRNA less effective for translation, resulting in reduction or elimination of protein expression.

In a preferred embodiment, caspase-8 is detected by immunoassay. For example, as exemplified *infra*, Western blotting permits detection of the presence or absence of caspase-8. Other immunoassay formats, *e.g.*, as discussed above in connection with *CASP8*-specific antibodies, can also be used in place of Western blotting.

Alternatively, a biochemical assay can be used to detect expression of caspase-8, *e.g.*, by the presence or absence of a band by polyacrylamide gel electrophoresis; by the presence or absence of a chromatographic peak by any of the various methods of high performance liquid chromatography, including reverse phase, ion exchange, and gel permeation; by the presence or absence of caspase-8 in analytical capillary electrophoresis chromatography, or any other quantitative or qualitative biochemical technique known in the art.

For both kinds of assays, biopsy tissue is obtained from a subject. The tumor cells should be purified from other tissue to ensure that contaminating *CASP8* from normal cells is not detected. Antibodies that are capable of binding to caspase-8 are then contacted with samples of the tissue under conditions that permit antibody binding to determine the presence or absence of caspase-8. In a further embodiment, antibodies that distinguish polymorphic variants of caspase-8 can be used. The antibodies may be polyclonal or monoclonal, preferably monoclonal.

Measurement of specific antibody binding to cells may be accomplished by any known method, *e.g.*, quantitative flow cytometry, or enzyme-linked or fluorescence-linked immunoassay. The presence or absence of a particular mutation, and its allelic distribution (*i.e.*, homozygosity vs. heterozygosity) is determined by comparing the values obtained from a patient with norms established from populations of patients having known polymorphic patterns.

The components for detecting caspase-8 protein can be conveniently provided in a kit form. In its simplest embodiment, a kit of the invention provides a caspase-8 detector, *e.g.*, a detectable antibody (which may be directly labeled or which may be detected with a secondary labeled reagent).

Anti-Tumor Gene Therapy

The term "anti-tumor gene therapy" as used herein refers to a gene therapy targeted to cells of a tumor, *i.e.*, cancer, which causes tumor necrosis, apoptosis, growth regulation, *i.e.*, regression or suppression of the tumor. In the practice of the present invention, anti-tumor gene therapy refers to administration or delivery of a gene encoding caspase-8, either alone or in combination with other genes effective for treating tumors.

Examples of anti-tumor gene therapies of the prior art include, but are by no means limited to, introduction of a suicide gene; introduction of an apoptosis gene; introduction of a tumor suppresser gene; and introduction of an oncogene antagonist gene. Preferably anti-tumor genes, such as *CASP8*, are supplemented with immunostimulatory genes to enhance recruitment and activation of immune effector cells. If a viral, such as adenovirus, vector is used (see, *e.g.*, PCT Publication No. WO 95/14101), the presence of adenoviral antigens could also provide an adjuvant effect to overall enhanced immune responsiveness.

"Gene therapy" refers to transfer of a gene encoding an effector molecule into cells, in this case of the tumor. Gene therapy vectors include, but are not limited to, viral vectors (including retroviruses and DNA viruses), naked DNA vectors, and DNA-transfection agent admixtures. Preferably, a therapeutically effective amount of the vectors are delivered in a pharmaceutically acceptable carrier. The phrase "therapeutically effective amount" is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50

percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host, *e.g.*, tumor progression, metastasises, or progression to the next stage of cancer. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host, *e.g.*, to induce remission, reduce tumor size or burden, or both, or increase the time from treatment until relapse. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such methods, including routes of administration and dose, are well known in the art. These are discussed in greater detail in a section directed to "Gene Therapy Vectors" below, as well as in the references disclosed therein.

Gene therapy in accordance with the invention can be used to treat any cancer, but particularly tumors with an amplified MYC oncogene. Preferably, caspase-8 is inactivated in the tumor cells of the cancer. However, this does not necessarily have to be the case: increasing the level of expression of caspase-8 beyond endogenous levels is expected to initiate cell death-inducing signaling. Alternatively, modified forms of caspase-8 (discussed *supra*) with enhanced death-inducing activity can be used in tumor cells that express wild-type caspase-8 endogenously. Furthermore, assays that detect expression (*e.g.*, Northern assays) or translation (*e.g.*, immunoassays) of *CASP8* may not differentiate a defective gene product from wild-type, thus delivery of the wild-type gene may be useful even if it appears that the cell expresses caspase-8.

As noted above, caspase-8 gene therapy of a tumor can be combined with other anti-tumor therapies, including but by no means limited to suicide gene therapy, anti-oncogene or tumor suppressor gene therapy, administration of tumor growth inhibitors, administration of angiogenesis inhibitors, immune therapies with an immunologically active polypeptide (including immunostimulation, *e.g.*, in which the active polypeptide is a cytokine, lymphokine, or chemokine, and vaccination, in which the active polypeptide is a tumor specific or tumor associated antigen), and conventional cancer therapies (chemotherapy and radiation therapy).

Suicide gene therapies. Introduction of genes that encode enzymes capable of conferring to tumor cells sensitivity to chemotherapeutic agents (suicide gene) has proven to be an effective anti-tumor gene therapy. A representative example of such a suicide gene is thymidine kinase of herpes simplex virus. Additional examples are thymidine kinase of varicella zoster virus and the bacterial gene cytosine deaminase which can convert 5-fluorocytosine to the highly toxic compound 5-fluorouracil.

The prodrug useful in the methods of the present invention is any that can be converted to a toxic product, *i.e.*, toxic to tumor cells. The prodrug is converted to a toxic product by the gene product of the therapeutic nucleic acid sequence in the vector useful in the method of the present invention. Representative examples of such a prodrug is ganciclovir, which is converted *in vivo* to a toxic compound by HSV-tk. Other representative examples of pro-drugs include acyclovir, FIAU [1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-5-iodouracil], 6-methoxypurine arabino-side for VZV-tk, and 5-fluorocytosine for cytosine deaminase.

Anti-oncogene and tumor suppresser gene therapies. Tumor initiation and progression in many cancer types are linked to mutations in oncogenes (*e.g.*, ras, myc) and tumor suppresser genes (*e.g.*, retinoblastoma protein, p53). A number of approaches are being pursued using anti-oncogene molecules including monoclonal antibodies, single chain antibody vectors, antisense oligonucleotide constructs, ribozymes and immunogenic peptides (Chen, Mol. Med. Today, 1997, 3:160-167; Spitz, *et al.*, Anticancer Res., 1996, 16:3415-3422; Indolfi *et al.*, Nat. Med., 1996, 2:634-635; Kijima *et al.*, Pharmacol. Ther., 1995, 68:247-267). Various strategies can be employed for tumor suppressor gene therapy, particularly with p53 (PCT Publication No. WO 94/24297) or analogues thereof such as CTS-1 (French Patent Application No. FR 08729).

Gene Therapy Vectors

As discussed above, a vector is any means for the transfer of a nucleic acid according to the invention into a host cell. Preferred vectors for transient expression are viral vectors, such as retroviruses, herpes viruses, adenoviruses and adeno-associated viruses. Thus, a gene encoding a functional caspase-8 protein or polypeptide domain fragment thereof can be introduced *in vivo*, *ex vivo*, or *in vitro* using a viral vector or through direct introduction of DNA. Expression in targeted tissues can be effected by targeting the transgenic vector to specific cells, such as with a viral vector or a receptor ligand, or by using a tissue-specific promoter, or both. Targeted gene delivery is described in PCT Publication No. WO 95/28494.

Viral vectors. Viral vectors commonly used for *in vivo* or *ex vivo* targeting and therapy procedures are DNA-based vectors and retroviral vectors. Methods for constructing and using viral vectors are known in the art (*see, e.g.*, Miller and Rosman, BioTechniques, 1992, 7:980-990). Preferably, the viral vectors are replication defective, that is, they are unable to replicate autonomously in the target cell. In general, the genome of the replication defective viral vectors which are used within the scope of the present invention lack at least one region which is necessary for the replication of the virus in the infected cell. These regions can either be eliminated (in whole or in part), be rendered non-functional by any technique known to a person skilled in the art. These techniques include the total removal, substitution (by other sequences, in particular by the inserted nucleic acid), partial deletion or addition of one or more bases to an essential (for replication) region. Such techniques may be performed *in vitro* (on the isolated DNA) or *in situ*, using the techniques of genetic manipulation or by treatment with mutagenic agents. Preferably, the replication defective virus retains the sequences of its genome which are necessary for encapsidating the viral particles.

DNA viral vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Thus, a specific tissue can be specifically targeted.

Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector (Kaplitt *et al.*, Molec. Cell. Neurosci., 1991, 2:320-330), defective herpes virus vector lacking a glyco-protein L gene (Patent Publication RD 371005 A), or other defective herpes virus vectors (PCT Publication Nos. WO 94/21807 and WO 92/05263); an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet *et al.* (J. Clin. Invest., 1992, 90:626-630; *see also* La Salle *et al.*, Science, 1993, 259:988-990); and a defective adeno-associated virus vector (Samulski *et al.*, J. Virol., 1987, 61:3096-3101; Samulski *et al.*, J. Virol., 1989, 63:3822-3828; Lebkowski *et al.*, Mol. Cell. Biol., 1988, 8:3988-3996).

A defective herpes simplex virus has been shown to be effective for delivery of genes, particularly to cells of the CNS (*see, e.g.*, Belloni *et al.*, Human Gene Therapy, 1996, 7:2015-24).

Recombinant defective adenoviruses have been used for transferring foreign genes into cells, particularly for gene therapy of tumors (as noted above), and for delivery of therapeutic genes to cells of the central nervous system. For example, PCT Publication Nos. WO 94/08026 and WO 94/08026 describe recombinant adenovirus vectors for the transfer of foreign genes into the central nervous system (CNS). Other examples of gene delivery to the CNS include the following: French Publication No. FR2717824 discloses adenoviruses containing DNA from glial derived neurophilic factors, which infected nerve cells very efficiently; various publications describe adenoviral vectors that express glial maturation factor (FR2717497), brain derived neurotropic factor (FR2717496) and acidic fibroblast growth factor (FR2717495); PCT Publication No. WO 95/26409 describes adenoviruses containing the DNA sequence for basic fibroblast growth factor to infect cells directly or via implants to treat neurological disorders; PCT Publication No. WO 96/00790 describes adenoviruses containing DNA encoding superoxide dismutase (SOD) to treat neurodegenerative diseases and excessive SOD expression; and PCT Publication No. WO 96/01902 describes adenoviruses expressing nitric oxide synthase for gene therapy where angiogenesis is required for treating disorders of the CNS.

Adenoviruses can be genetically modified to reduce the levels of viral gene transcription and expression, including adenoviruses defective in the E1 and E4 regions (PCT Publication No. WO 96/22378) and adenoviruses with an inactivated E1 region but also with

altered genomic organization reducing the number of viable viral particles produced if recombination occurs with the host genome (PCT Publication No. WO 96/13596). PCT Publication No. WO 96/10088 describes defective adenoviruses with an inactivated IVa2 gene. PCT Publication No. WO 95/02697 describes an adenovirus defective in regions E1 and E2, E4, or L1-L5.

Combination virus ("plasmovirus") vectors. In another embodiment, a gene can be introduced using a combined virus, also termed plasmovirus (Genopoeitic, France) vector system. Plasmovirus systems permit one cycle of infectious virus formation in infected host cells. In these systems, a complementing gene(s) for defective viral genome sequences and the defective viral sequences are both provided to target cells *in vivo* or *in vitro*. The primary infected cells produce infectious, defective virus. By permitting one cycle of infectious defective virus formation in infected cells, plasmovirus technology amplifies gene delivery *in vitro* and, particularly, *in vivo*. This cycle of infectious virus formation *in situ* permits wider infection of tumor cells in a tumor, thus enhancing the anti-tumor effect and reducing reliance on the bystander effect. See PCT Publication Nos. WO 95/22617, WO 95/26411, WO 96/39036, WO 97/19182.

Non-viral vectors. Alternatively, the vector can be introduced *in vivo* by lipofection, as naked DNA, or with other transfection facilitating agents (peptides, polymers, etc.). Synthetic cationic lipids can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker (Felgner *et al.*, Proc. Natl. Acad. Sci. USA, 1987, 84:7413-7417; Felgner and Ringold, Science, 1989, 337:387-388; see Mackey *et al.*, Proc. Natl. Acad. Sci. USA, 1988, 85:8027-8031; Ulmer *et al.*, Science, 1993, 259:1745-1748). Useful lipid compounds and compositions for transfer of nucleic acids are described in PCT Publication Nos. WO 95/18863 and WO 96/17823, and in U.S. Patent No. 5,459,127. Lipids may be chemically coupled to other molecules for the purpose of targeting (see Mackey *et al.*, *supra*). Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

Other molecules are also useful for facilitating transfection of a nucleic acid *in vivo*, such as a cationic oligopeptide (e.g., PCT Publication No. WO 95/21931), peptides derived

from DNA binding proteins (*e.g.*, PCT Publication No. WO 96/25508), or a cationic polymer (*e.g.*, PCT Publication No. WO 95/21931).

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, *e.g.*, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (*see, e.g.*, Wu *et al.*, J. Biol. Chem., 1992, 267:963-967; Wu and Wu, J. Biol. Chem., 1988, 263:14621-14624; Canadian Patent Application No. 2,012,311; Williams *et al.*, Proc. Natl. Acad. Sci. USA, 1991, 88:2726-2730). Receptor-mediated DNA delivery approaches can also be used (Curiel *et al.*, Hum. Gene Ther., 1992, 3:147-154; Wu and Wu, J. Biol. Chem., 1987, 262:4429-4432). US Patent Nos. 5,580,859 and 5,589,466 disclose delivery of exogenous DNA sequences, free of transfection facilitating agents, in a mammal. Recently, a relatively low voltage, high efficiency *in vivo* DNA transfer technique, termed electrotransfer, has been described (Mir *et al.*, C.P. Acad. Sci., 1998, 321:893; PCT Publication Nos. WO 99/01157, WO 99/01158, and WO 99/01175).

Combination Therapies

The present invention provides for further enhancement of the anti-tumor effect by including additional anti-tumor treatments with the anti-tumor gene. For example, the present invention contemplates further combinations with tumor growth inhibitors, anti-angiogenesis treatment, tumor antigen and whole tumor vaccines, chemotherapeutic agents, radiation, and surgery (tumor resection).

Tumor growth inhibitors. The term "tumor growth inhibitor" is used herein to refer to a protein that inhibits tumor growth, such as but not limited to interferon (IFN)- γ , tumor necrosis factor (TNF)- α , TNF- β , and similar cytokines. Alternatively, a tumor growth inhibitor can be an antagonist of a tumor growth factor. Such antagonists include, but are not limited to, antagonists of tumor growth factor (TGF)- β and IL-10. The present invention contemplates administration of tumor growth inhibitor proteins systemically, or alternatively by gene therapy. In a specific gene therapy embodiment, the gene therapy vector is administered directly to the tumor.

Anti-angiogenic factors. Tumor angiogenesis is an integral part of tumor

progression and a variety of therapies targeted to inhibit angiogenesis are under development as cancer therapies. Anti-angiogenesis molecules vary from anti-angiogenic proteins to small molecules that block growth factor receptor mediated effects. Anti-angiogenesis therapies primarily reverse the growth/apoptosis balance of the tumor and induce dormancy. Once the administration of these therapies is halted, angiogenesis can resume and tumor growth progresses.

An "anti-angiogenic factor" is a molecule that inhibits angiogenesis, particularly by blocking endothelial cell migration. Such factors include fragments of angiogenic proteins that are inhibitory (such as the ATF of urokinase), angiogenesis inhibitory factors, such as angiostatin (O'Reilly *et al.*, Cell, 1994, 79:315-328) and endostatin; tissue inhibition of metalloproteinase (Johnson *et al.*, J. Cell. Physiol., 1994, 160:194-202); soluble receptors of angiogenic factors, such as the urokinase receptor or FGF/VEGF receptor (Wilhem *et al.*, FEBS Letters, 1994, 337:131-134); molecules which block endothelial cell growth factor receptors (O'Reilly *et al.*, Cell, 1997, 88:277-285; O'Reilly, Nat. Med., 1996, 2:689-692), and Tie-1 or Tie-2 inhibitors. Generally, an anti-angiogenic factor for use in the invention is a protein or polypeptide, which may be encoded by a gene transfected into tumors using vectors of the invention. For example, the vectors of the invention can be used to deliver a gene encoding an anti-angiogenic protein into a tumor in accordance with the invention.

Immune activation. Administration of various immunostimulatory molecules (cytokines, lymphokines, and chemokines, for example), such as CM-CSF and IL-2, can stimulate any immune response in conjunction with the tumor suppressor activity of caspase-8. The immunostimulatory molecules can be delivered as proteins, *e.g.*, by intravenous injection, or as therapeutic expression vectors, for expression in the host.

In order to increase the tumor antigen specific immune response, one could introduce defined tumor associated antigens (TAA) in the system to specifically increase the level of antigen. These TAA could be introduced as cells, cell extracts, proteins, or peptides, or alternatively as genes in any viral or non-viral expression vectors. Besides the defined antigen based vaccines, a number of vaccine strategies are being explored in the laboratory as well as in the clinic. One well researched strategy in animal models is the modification of autologous or allogeneic tumor cell using cytokine genes (*e.g.*, IL-2, GM-CSF, IL-12, IL-4) as well as some key

costimulatory molecule genes (e.g., B7.1, B7.2). These gene modified tumor vaccines prove the concept of breaking peripheral tolerance and anergy using immunological mechanisms (Clary *et al.*, Cancer Gene Ther., 1997, 4:97-104; Gilboa, Semin. Oncol., 1996, 23:101-107).

Chemotherapeutic agents, radiation, and surgery (tumor resection). Although the methods of the invention are effective in inhibiting tumor growth and metastasis, the vectors and methods of the present invention are advantageously used with other treatment modalities, including without limitation surgery, radiation, chemotherapy, and other gene therapies.

For example, the vectors of the invention can be administered in combination with nitric oxide inhibitors, which have vasoconstrictive activity and reduce blood flow to the tumor.

In another embodiment, a vector of the invention can be administered with a chemotherapeutic such as, though not limited to, taxol, taxotere and other taxoids (e.g., as disclosed in U.S. Patent Nos. 4,857,653; 4,814,470; 4,924,011, 5,290,957; 5,292,921; 5,438,072; 5,587,493; European Patent No. EP 253 738; and PCT Publication Nos. WO 91/17976, WO 93/00928, WO 93/00929, and WO 96/01815), or other chemotherapeutics, such as cis-platin (and other platinum intercalating compounds), etoposide and etoposide phosphate, bleomycin, mitomycin C, CCNU, doxorubicin, daunorubicin, idarubicin, ifosfamide, and the like.

Screening and Chemistry

Identification of the role of CASP8 in cancer provides for development of screening assays, particularly for high throughput screening of molecules that agonize or antagonize the activity of CASP8. In particular, indicator cells that are specially engineered to indicate the activity of CASP8, particularly initiation of the death process, can serve as targets to identify either a CASP8 inducer or replacement.

For example, in one embodiment, cells in which a *CASP8* gene is inactivated are contacted with a candidate compound and cell apoptosis is evaluated or detected. Such an assay will identify CASP8 agonists, *i.e.*, molecules that re-activate CASP8 expression (such as 5-aza-2'-deoxycytidine), or substitutes, *i.e.*, that activate the death pathway in the absence of CASP8. In a preferred embodiment of the invention, cells in which *CASP8* is inactivated because of methylation of the promoter are used in the assay. Candidate compounds that lead to caspase-8

expression or initiation of apoptosis are selected for their ability to overcome the promoter methylation.

In an alternative embodiment, cells that express caspase-8 (whether endogenously or by genetic engineering) are contacted with a candidate compound and cell apoptosis is evaluated or detected. Such an assay will indentify CASP8 antagonists, *i.e.*, molecules that inhibit CASP8 activity and prevent initiation of the cell death pathway.

Accordingly, the present invention contemplates methods for identifying specific agonists and antagonists of CASP8 activity using various screening assays known in the art.

Any screening technique known in the art can be used to screen for CASP8 agonists or antagonists. The present invention contemplates screens for synthetic small molecules as well as screens for natural molecules that agonize or antagonize the activity of CASP8 *in vivo*. For example, natural products libraries can be screened using assays of the invention for molecules that agonize or antagonize CASP8 activity.

One approach uses recombinant bacteriophage to produce large libraries. Using the "phage method" (Scott and Smith, Science, 1990, 249:386-390; Cwirla, *et al.*, Proc. Natl. Acad. Sci. USA, 1990, 87:6378-6382; Devlin *et al.*, Science, 1990, 49:404-406), very large libraries can be constructed (10^6 - 10^8 chemical entities). A second approach uses primarily chemical methods, of which the Geysen method (Geysen *et al.*, Molecular Immunology, 1986, 23:709-715; Geysen *et al.* J. Immunologic Method, 1987, 102:259-274; and the method of Fodor *et al.* (Science, 1991, 251:767-773) are examples. Furka *et al.* (14th International Congress of Biochemistry, 1988, Volume #5, Abstract FR:013; Furka, Int. J. Peptide Protein Res., 1991, 37:487-493), and U.S. Patent Nos. 4,631,211 and 5,010,175 describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

In another aspect, synthetic libraries (Needels *et al.*, Proc. Natl. Acad. Sci. USA, 1993, 90:10700-4; Ohlmeyer *et al.*, Proc. Natl. Acad. Sci. USA, 1993, 90:10922-10926; PCT Publication Nos. WO 92/00252 and WO 94/28028) and the like can be used to screen for CASP8 ligands according to the present invention.

Various reporter gene assays can be used to evaluate initiation of the death-inducing signaling complex. In a specific embodiment, *infra*, a green fluorescent protein

expression assay permits evaluation of caspase-8 activity. GFP has been modified to produce proteins that remain functional but have different fluorescent properties, including different excitation and emission spectra (U.S. Patent No. 5,625,048 and PCT Publication No. WO 98/06737); an enzyme recognition site (PCT Publication No. WO 96/23898); increased intensity compared to the parent proteins (PCT Publication No. WO 97/11094); higher levels of expression in mammalian cells (PCT Publication No. WO 97/26633); twenty times greater fluorescence intensity than wild-type GFP (PCT Publication No. WO 97/42320); and mutants excitable with blue and white light (PCT Publication No. WO 98/21355). Other reporter genes include luciferase, β -galactosidase (β -gal or lac-Z), chloramphenicol transferase (CAT), horseradish peroxidase, and alkaline phosphatase. In addition, expression of almost any protein can be detected using a specific antibody.

Reporter gene expression can be tied to expression or activation of any component of the DISC system. In a specific example, *infra*, a GFP-expression vector containing the death receptor DR3 was used to evaluate caspase-8 activity. Other DISC proteins, such as the Fas receptor, FADD, FasL, FAP, FAF, Trail/DR-2, TNFRp55, TRADD, RIP, and L32 can be similarly modified. In these assays, candidate compound can be tested for their ability to inhibit apoptosis in cells that express caspase-8, or for their ability to initiate apoptosis in cells in which caspase 8 is inactivated.

EXAMPLES

The following Examples are provided to illustrate the invention without being limiting in any way.

EXAMPLE 1: Structure and Chromosome Localization of the Human CASP8 Gene

This Example describes isolation of the human gene corresponding to caspase-8, *CASP8*, and determination of its structure and chromosomal location. The present study details this characterization, *EcoRI* and *HindIII* restriction fragment length polymorphisms (RFLPs), and demonstrates that *CASP8* is localized to human chromosome 2 band q33-34, a region frequently deleted in human tumors. These results permit further study of the apoptotic signaling pathway in

tumor cells.

Materials and Methods

Isolation and characterization of the human CASP8 genomic clones. Human caspase-8 cDNAs were obtained by computer analysis of a human EST library (Washington University-NCI Human EST Project). Three EST cDNAs were isolated. DNA sequencing of the caspase-8 EST DNAs was carried out as previously described using automated fluorescent-based DNA sequence analysis using Perkin Elmer/Applied Biosystems Division DNA sequencers models 373-377, with TaqFS enzyme and multiple oligonucleotide primers derived from the published cDNA sequence (Muzio *et al.*, Cell, 1996, 85:817; Boldin *et al.*, Cell, 1996, 85:803). Oligonucleotides were spaced approximately 80-100 bp apart spanning the cDNA. All DNA sequence data was analyzed using the IntelliGenetics program.

The human *CASP8* gene was isolated from a human BAC genomic library (Genome Systems, Inc.) by hybridization with the corresponding human cDNA. Two BAC clones containing *CASP8* related DNA sequences were identified (clones BAC43 and BAC 44 with the clone addresses BACH 43(K10) and BACH 44(M7); Genome Systems, Inc., St. Louis, MO). Their identity was confirmed by DNA sequence analysis of the entire coding region, the 3' UTR, and a portion of the 5' untranslated region (UTR). In addition, when necessary, *HindIII* fragments containing the entire gene were subcloned into pKS, and the resulting plasmid DNA used for double strand DNA sequence analysis. Using oligonucleotide primers designed for sequencing the cDNA clones, all exons and intron/exon boundaries were sequenced in both directions. Oligonucleotides were spaced approximately 80-100 bp apart spanning the cDNA. All DNA sequence data was analyzed using the IntelliGenetics program.

Southern and Northern blotting. Genomic DNA was isolated from cell lines as previously described (Amann *et al.*, Genom, 1996., 32:260-265). Ten micrograms was then digested with either *EcoRI* or *HindIII*, the DNA fragments resolved by agarose gel electrophoresis in 1X TAE buffer, and the DNA transferred to Duralose membrane (Stratagene, San Diego, CA). These Southern blots were then hybridized with a [³²P-γ-dCTP]-labeled full length caspase-8 cDNA fragment overnight at 42°C as described previously. The filters were then washed 3X with 2XSSC at 42°C and 1X with 2XSSC at 68°C and the blots visualized by exposure to Kodak

XAR-5 film for six days at -80°C.

Northern blots (total human tissue, human fetal tissue, and human lymphoid tissue) were obtained from Clontech (Palo Alto, CA). Hybridizations and washes were performed exactly as described for Southern blotting. These Northern blots were visualized by exposure to Kodak XAR-5 film at -80°C for four days. Equivalent levels of mRNA were confirmed by hybridization to a β -actin cDNA (data not shown).

Fluorescent in situ hybridization (FISH) analysis. Bromodeoxyuridine-synchronized and phytohemagglutinin-stimulated peripheral blood lymphocytes from a normal male donor were used as the source of metaphase chromosomes for the chromosomal localization studies. Purified DNA from BAC clones containing the human *CASP8* gene (*CASP 43* and *CASP 44*) were labeled for FISH analysis by nick-translation with digoxigenin-11-UTP (Boehringer Mannheim). Slides were baked at 55°C for one hour, RNase treated, denatured in 70% formamide/2X SSC for two minutes at 70°C, and denatured with 100% ethanol. The labeled probe was denatured and hybridized to the chromosomes overnight in the presence of 50% formamide, 10% dextran sulfate, and human COT-1 genomic DNA. Washes were performed at 46°C. To confirm the localization of the human *CASP8* gene, one set of metaphase chromosomes was simultaneously hybridized with a biotin labeled genomic heterochromatin specific clone on human chromosome 2 (Oncor, Inc.) Specific hybridization signals were detected by incubating the hybridized slides in fluorescein-conjugated sheep antibodies to digoxigenin (Boehringer Mannheim). Two color specific probe signals were detected by incubating the hybridized slides in fluorescein-conjugated sheep antibodies to digoxigenin and Texas red Avidin (Vector Labs). All of the mitotic figures examined placed *CASP8* at 2q33-34 (Figure 3); band assignment was determined by measurement of twenty chromosomes 2.

Results and Discussion

Structure of the human CASP8 gene. Southern hybridization of human genomic DNA with the caspase-8 cDNA probe yields a pattern consistent with a single-copy gene contained within both BAC clones (data not shown). *CASP8* contains 10 exons spanning ~30 kb as shown in Figure 1 (GenBank accession numbers for *CASP8* sequences are:

AF102139-102146). The 5' UTR is contained in three exons, while the 3' UTR is encoded by one exon. The open reading frame (ORF) begins in exon 3 (Figure1A). Sequences of exons 3, 4, 5, 6, 7, 8, 9, and 10, including partial sequences of the flanking introns, were determined. These sequences are depicted in SEQ ID NOS:3-10, respectively. All of the exon/intron splice junction regions, as well as the exons themselves, were analyzed (Table 1). (The boundaries in Table 1 permit identification of the coding and non-coding parts of the genomic sequences of SEQ ID NOS:3-10, and thus deduction of the amino acid sequence of the polypeptide segment encoded by each exon.) In each instance but one (*i.e.*, splice acceptor site of intron 4/exon5), the donor and acceptor splice junction sequences conform to the GT/AG rule (Breathnach *et al.*, Ann. Rev. Biochem., 1981, 50:349-383). One of the DEDs is contained entirely in exon 3, while the second DED is contained in exons 4 and 5. The linker region of caspase-8, located between the DEDs and the cysteine protease domain, is encoded by exons 6-8. All of these exons are relatively small in size, ranging from 45-142 bp (Figure 1). Exons 9-10 contain the large and small subunits that constitute the cysteine protease catalytic domain. Much of this cysteine protease domain, including the catalytic cysteine residue (QACXG) (SEQ ID NO:11) of the large subunit and the substrate specificity determinants of the small subunit (RNPAEGTW) (SEQ ID NO:12), are found in exon 9.

TABLE 1
Exon/Intron Boundaries of the Human *CASP8* Gene ORF.

Exon	Exon/Intron Sequence	SEQ ID NO	Intron	Exon/Intron Sequence	SEQ ID NO	Exon
2	..GGTGGAGCGGgtgtgggtcg..	13	2	.. tattttgacttagATTATATTCT ..	14	3
3	..GCC TAC Aggtgggtggaaactc..	15	3	..cccaaccacaaagG GTC ATG..	16	4
4	..GAT GAC ATGgtgcctgggaac..	17	4	..ttctcctcctttacAAC CTG..	18	5
5	..TTC AGC AAAgtaccgcaatttc..	19	5	..tttgcttatctgagGAG AGA..	20	6
6	..TCA AAT gtagttaattactat..	21	6	..tcccggttttcccgagGGG GAG..	22	7
7	..TCA CAGgtagcacggaacc..	23	7	..gggttttgtaatccagACT TTG..	24	8
8	..GAT GCA Ggtggcggggctc..	25	8	..agtttcacttttcagGG GCT TTG..	26	9
9	..TGT CCT Cggtagttttgcctact..	27	9	..gtgaatagtttgcagA GGC GAT..	28	10

Notes to Table 1: Upper case letters correspond to the ORF; lower case letters to intronic sequences. The triplet codons are shown for the ORF at the exon/intron boundaries. All splice donor and acceptor sites fit the consensus sequence, except for the one in bold and underlined.

The structure of the human *CASP8* gene is identical to the mouse with regard to the exon/intron organization and exon size (Sakamaki *et al.*, Eur. J. Biochem., 1998, 253:399-405). The sequence of the exon/intron boundaries is shown in Table 1. The structure of the mouse gene, corresponding to the ORF portion of the mRNA, is encoded by eight exons. This is identical to the eight exons (*i.e.*, exons 3-10) that encode the human ORF. However, the 5' UTR of the mouse gene was not analyzed (Sakamaki *et al.*, 1998, *supra*). A similar exon/intron organization, with respect to the structural domains of the corresponding protein, has also been described for a close relative of *CASP8*, *CASP10* (Rasper *et al.*, Cell Death & Diff., 1998, 5:271-288). At least eight different isoforms of caspase-8, all generated by alternative splicing, have been reported (Boldin *et al.*, 1996, *supra*). We can confirm that the transcripts are, indeed, alternatively spliced products generated from the *CASP8* gene that correspond to specific exons (Figure 1). The function of several of these alternatively spliced caspase-8 products is currently unknown, but others have reported that only two of these isoforms are found in much abundance in the human cell lines they examined (Scaffidi *et al.*, J. Biol. Chem., 1997, 272:26953). Finally, BAC 43 and BAC 44 also contain the *CASP10* gene, as confirmed by both PCR and limited DNA sequence analysis of the first and last exons of the gene (Figure 1). The *CASP10* gene is located ~20-30 kb 5' of the *CASP8* gene in the same transcriptional orientation.

Southern and Northern blot analysis of CASP8, and two RFLPs associated with the gene. Southern blot analysis of total genomic DNA from three different human neuroblastoma cell lines was performed to determine whether restriction fragment length polymorphisms are associated with *CASP8* (Figure 2). Two different restriction enzymes, *EcoRI* and *HindIII*, were associated with RFLPs in *CASP8*. The *EcoRI* polymorphism involved a 4.7 kb band that increased to about 8.0 kb (Figure 2A, NB5). Interestingly, the same cell line also had a *HindIII* RFLP involving a 4.0 kb band that increased in size to ~7.2 kb (Figure 2B, NB5). These RFLPs can now be used to track specific alleles associated with *CASP8* in families and/or individuals with different genetic diseases/cancer to determine whether this gene is a candidate for

mutation.

Northern blot analysis of human adult tissues demonstrated that caspase-8 mRNA is expressed fairly ubiquitously (data not shown). Testis, skeletal muscle and kidney express very little caspase-8, while brain appears to express extremely high levels of this mRNA. This is in agreement with previously reported results for the tissue distribution of caspase-8 mRNA (Boldin *et al.*, 1996, *supra*). Of some interest is the expression of this gene in human lymphoid tissues, including spleen, lymph node, thymus, peripheral blood leukocytes (PBLs), bone marrow, and fetal liver, particularly those that undergo significant apoptosis. Northern blot analysis of these tissues shows that caspase-8 is expressed (data not shown). The highest level of expression was found in PBLs, consistent with caspase-8's role in the death of peripheral T cells. Lymph node and spleen also expressed significant levels of caspase-8 mRNA, while thymus, bone marrow, and fetal liver expressed very low levels.

CASP8 mRNA expression was also evaluated in fetal tissues (embryonic RNAs, in addition to liver). While human fetal brain expressed undetectable levels of caspase-8 mRNA, and human fetal liver and lung expressed low levels of caspase-8 mRNA, human fetal kidney expressed the highest level of caspase-8 mRNA (data not shown), similar to what has been reported during the mouse development (Varfolomeev *et al.*, Immunity, 1998, 9:267-276).

Chromosome localization of the human CASP8 gene. By fluorescent *in situ* hybridization (FISH) analysis, the *CASP8* gene is localized to human chromosome band 2q33-34 (Figures 3A and 3B). This assignment was confirmed by somatic cell hybrid analysis (data not shown) and it is consistent with the report of another group. While this research was in progress Rasper *et al.*, *supra*, reported that they had identified the 5' UTR of *CASP8* in a genomic PAC clone containing the *CASP10* and *USURPIN* genes, and that this PAC localized to 2q33-34. This is also the chromosome region the human *CASP10* gene was localized to by Fernandes-Alnemri *et al.*, Proc. Natl. Acad. Sci. USA, 1996, 93:7464-7469, suggesting that all of these genes may have arisen by tandem duplications. Analysis of our BAC clones indicates that *CASP10* is approximately 30 kb from the 5' end of *CASP8*. Tandem duplication of other caspases, *e.g.*, *CASP1*, *CASP4*, and *CASP5* at 11q22.2-22.3 (Nasir *et al.*, Mam. Genome, 1997, 8:611-613), as well as several functional death receptors and their decoys, *e.g.*, *DR4*, *DR5*, *DcR1*, and *DcR2* at

8p21 (Golstein, 1997, Curr. Biol, 7:R750-753), have been observed.

Human gene duplications of this type have been associated with other chromosome regions that are altered during tumorigenesis (Baens *et al.*, Genom., 1995, 29:44-52). Such duplications may reflect the relative instability of these chromosomal DNA regions (Baens *et al.*, 1995, *supra*). In fact, current physical and genetic mapping have demonstrated that this region of chromosome 2 is frequently involved in tumorigenesis. Several studies have shown that there is frequent loss of heterozygosity (LOH) and the 2q33 region in a number of human tumors, including small-cell lung carcinoma, non-small-cell lung carcinoma, colorectal carcinoma, neuroblastoma and uterine cervical carcinoma (Kohno *et al.*, Oncology, 1994, 9:103-103; Takita *et al.*, Oncology, 1995, 11:1829-1834). This has led to speculation that a tumor suppressor gene is located in this region of chromosome 2 (Kohno *et al.*, 1994, *supra*). The data in Example 2 unexpectedly indicate that *CASP8* is such a tumor suppressor, which is consistent with its function as an effector of apoptotic signaling pathways. The identification of *EcoRI* and *HindIII* RFLPs should facilitate this type of analysis.

Additional studies, shown in Example 2, have established that abnormalities in the structure and/or regulation of *CASP8* occur in specific tumors. Recently, Evan and colleagues (Heuber *et al.*, Science, 1997, 278:1305-1309) demonstrated that the apoptosis associated with c-myc overexpression was mediated by the Fas pathway. The authors proposed that, given their role in apoptotic signaling, aberrant regulation of one or more of the genes corresponding to components of this pathway may be observed in certain transformed cells, particularly those with elevated levels of myc oncoproteins. It is only now that the structure and localization of *CASP8* is known that it is possible to examine these types of tumors to determine aberrant expression of caspase-8.

**EXAMPLE 2: CASP8 Inactivation in Human Neuroblastoma
and Small Cell Lung Carcinoma**

Materials and Methods

Materials and methods for this Example are substantially the same as those described in Example 1.

Neuroblastoma cell lines NB1-8, NB10, and NB12-21 from St. Jude Children's Research Hospital were tested. In addition, Memorial Sloan Kettering neuroblastoma cell lines SK-N-AS, SK-N-F1, and SK-N-DZ, and NIH small-cell lung carcinoma cell lines NCIH 889, NCIH 810, NCIH H69, HCIH H82, and NCIH N417 were analyzed. HeLa and Jurkat lines were used as controls.

Results

Southern blot and FISH analysis of genomic DNA from neuroblastoma cell lines. Blots with genomic DNA from the NB cell lines were hybridized with the caspase-8 cDNA and with a caspase-10 cDNA. It was found that with line NB7, there is no hybridization signal with the caspase-8 probe, but the caspase-10 probe detected its corresponding gene. The *CASP10* gene is about 30 kb from the 5' end of *CASP8* (Example 1). Therefore, Southern analysis demonstrates that *CASP8* is homozygously deleted from NB7 (indicated by -/-).

As all other neuroblastoma cell lines tested by Southern analysis were positive for *CASP8* genomic DNA (Figures 4A and 4B), we decided to investigate whether some of these cell lines contained hemizygous deletions of *CASP8*. Indeed, when fluorescent *in situ* hybridization (FISH) analysis with the human *CASP8* BAC genomic clone was used to determine whether the ~150 kb encompassed by this clone, containing the entire *CASP8* gene, was deleted from the cells, it revealed allelic loss in five of the eighteen NB cell lines examined (Table 2, indicated by +/-). In one example with the NB20 cell line, three chromosomes-2 contained *CASP8* signals, while three others did not. The ratio of chromosomes-2 with *CASP8* signals to chromosomes-2 without *CASP8* signals for other cell lines was 18% (NB-2), 78% (NB-13), 75% (NB-15), and 68% (NB-19), respectively.

The small size of the 2q33 deletions in NB7 did not allow their detection by conventional FISH using the BAC clone. Fiber FISH analysis of NB7 with smaller P1 phage clones, containing either *CASP8* or *CASP10*, demonstrated that one allele was missing much of *CASP10* and *CASP8*, while the other allele had an ~20-35 kb deletion encompassing the immediate *CASP8* region and did not affect *CASP10* (Figures 3C and 3D).

Northern blot analysis of RNA from the neuroblastoma cell lines. Northern analysis indicated that the approximately 3.0 kb *CASP8* mRNA is present in only NB5, NB15,

NB16, and NB21 (as well as the control HeLa cell line) (Figure 4C). These data coincide with the RNase protection data, except that the more sensitive RNase protection analysis demonstrated that NB3 cells also express very low levels of *CASP8* mRNA (Figure 5 and discussed below).

Western blot analysis of the caspase-8 protein in the various neuroblastoma cell lines from SJCRH (NB1-NB21) and Memorial Sloan Kettering (SK), and small-cell lung carcinoma cell lines (NCIH). Examination of caspase-8 expression by immunoblot analysis demonstrated that the protein was undetectable in cell lines lacking detectable mRNA (Figure 4D). Thus, the caspase-8 protein was detected only in NB3, NB5, NB15, NB16, and NB21 (HeLa and Jurkat served as positive controls). In addition, only one of the SK cell lines (SK-N-AS) and two of the NCIH small-cell lung carcinoma lines (NCIH 889 and NCIH 810) express caspase-8 protein (Figure 4D). Furthermore, amplification and expression of *MYCN* was highly correlated with the loss of *CASP8* expression (Figure 4E and Table 2). By contrast, caspase-10 was detected in each of the NB cell lines, indicating that alterations selectively affect caspase-8 expression.

TABLE 2

Analysis of *CASP8* in human neuroblastoma cell lines

Cell Line	<i>CASP8</i> (FISH)	Casp8 mRNA	Casp8 Protein	<i>CASP8</i> Methylation	<i>CASP8</i> Mutation	Casp10 Protein	FasR Protein	DR3 ¹ Protein	Fas mAb-Apoptosis	MYCN Protein	<i>MYCN</i> ²
NB1	+/+	-	N	Y	N	Y	N	Y	N	Low	2-6
NB2	+/-	-	N	Y	N	Y	Y	Y	N	High	>20
NB3	+/+	+/-	Y	N	N	Y	Y	N	Y	No	2
NB4	+/+	-	N	Y	N	Y	N	Y	N	High	>20
NB5	+/+	+	Y	N	N	Y	N	Y	Y	Mod	2-5
NB6	+/+	-	N	Y	N	Y	N	Y	N	High	>20
NB7	-/- ⁽³⁾	-	N	N	N	Y	N	Y	N	Mod	>20
NB8	+/+	-	N	Y	N	Y	Y	N	N	High	>20
NB10	+/+	-	N	Y	N	Y	Y	N	N	High	>20
NB12	+/+	-	N	Y	N	Y	N	Y	N	High	>20
NB13	+/-	-	N	Y	N	Y	N	Y	N	High	>20
NB14	+/+	-	N	Y	N	Y	N	Y	N	Low	>20
NB15	+/-	+	Y	N	N	Y	N	Y	N	No	>20
NB16	+/+	+	Y	N	N	Y	Y	Y	Y	V. Low	2-4
NB17	+/+	-	N	Y	N	Y	N	Y	N	Mod	>20
NB19	+/-	-	N	Y	N	Y	Y	Y	N	High	>20
NB20	+/-	-	N	Y	N	Y	Y	Y	N	Low	>20
NB21	+/+	+	Y	N	N	Y	Y	N	Y	Low	2-6

HeLa	+/+	+	Y	N	N	Y	N	N	N	ND	ND
------	-----	---	---	---	---	---	---	---	---	----	----

¹ From Grenet *et al.*, Genomics, 1998, 49: 385-393.

² From Beltinger *et al.*, Cancer Res., 1995, 55: 2053-2055, and references therein.

³ Both *CASP8* alleles have been deleted in this cell line as determined by Southern blotting.

5

RNase protection analysis of mRNAs from the various neuroblastoma cell lines.

RNA from each of the indicated neuroblastoma cell lines was examined for the expression of various cell death components: FasL, FasR, FADD, DR-3, FAP, FAF, TRAIL/DR-2, TNFRp55, TRADD, RIP, L32, and GAPDH (Figure 5). As was found with the Northern and Western blot analyses, only NB3, NB5, NB15, NB16, and NB21 express detectable caspase-8 mRNA. All of the other essential death components are expressed in every cell line.

10

Discussion

These data show that inactivation of caspase-8, whether by gene deletion, mutation, or suppression of expression, associates with cancer, and particularly with neuroblastoma. Thus, diagnosis and prognosis of cancer, especially neuroblastoma, can be based on the level or absence of caspase-8 expression.

These data establish an important role for caspase-8 in tumor suppression. Work with p53 and other tumor suppressor genes has established a role for gene therapy in treating various cancers. Caspase-8 is also indicated as a therapeutic tumor suppressor gene. Vectors for expression of caspase-8 will be useful in tumor cells in which caspase-8 has been inactivated. In addition, overexpression of caspase-8 in other tumor cells is expected to induce apoptosis and cell death.

20

EXAMPLE 3: Investigation of Silencing of *CASP8* by Methylation Using Methylation-Sensitive PCR Analysis. Study of Association Between *CASP8* Methylation and *MYCN* Gene Amplification in Neuroblastoma Patient Samples and Cell Lines

25

Materials and Methods

Bisulfite treatment. Five micrograms each of *EcoRI*-digested DNA from cultured cells was denatured with 1/10 volume of 3M NaOH at 37°C for 15 min. A freshly prepared

30

solution (1.2 ml) containing sodium metabisulfite (2.5M, pH 5.0) and hydroquinone (100 mM) was added to the denatured DNA and incubated at 55°C for 6 hrs. The bisulfite salts were removed by a Wizard desalting column (Promega, Madison, WI) according to the manufacturer's specifications. DNA in 100 microliters was desulphonated by addition of 1/10 volume of freshly prepared 3M NaOH and incubation at 37°C for 15 min, before neutralizing with 166 microliters of ammonium acetate (pH 7.0) and precipitating with 2.5 volumes of ethanol. Bisulfite modified DNA was resuspended in 40 microliters of water.

PCR amplification and Primers. Amplification of the 5' untranslated region of *Casp8* gene was performed in 50 microliters reaction mixtures containing 5 microliters of bisulfite treated DNA, dNTPs, each at 1.25 mM, 300 ng of each primer, 1xPCR buffer (Promega, Madison, WI) plus 6.7 mM MgCl₂ and 2.5 units of AmpliTaq polymerase (Promega).

Primer sets were designed to produce a 320 bp fragment in the upstream region of *Casp8* gene extending from +221 to +541. Wild type primers were used to amplify the corresponding region from 100 ng of untreated genomic DNA. Controls without DNA were performed for each set of PCR primers. DNA not treated with bisulfite (unmodified) failed to amplify with either set of methylated or unmethylated specific primers, but readily amplified with the wild type primers- primers specific for the sequence before modification. Primers for methylated -specific bisulfite treated DNA were:

- 1) Sense 5' TAGGGGATTTCGGAGATTGCGA 3' (SEQ ID NO:29)
- 2) Antisense 5' CGTATATCTACATTGAAACGA 3' (SEQ ID NO:30)

Primers for unmethylated-specific bisulfite treated DNA were:

- 1) Sense 5' TAGGGGATTGAGATTGTGA 3' (SEQ ID NO:31)
- 2) Antisense 5' CCATATATATCTACATTCAAACAA 3' (SEQ ID NO:32)

Primers for amplifying the corresponding wild type DNA (untreated with bisulfite) were:

- 1) Sense 5' TAGGGGACTCGGAGACTGCGA 3' (SEQ ID NO:33)
- 2) Antisense 5' CGTGTATCTGCATTGAGGCG 3' (SEQ ID NO:34)

Reactions were hot-started at 95°C for 5 min before the addition of AmpliTaq polymerase. Amplification was done under the following conditions: 35 cycles of 95°C for 30

sec, 58 c for the unmethylated primers and for the wild-type primers, or 64°C for the methylated primers, for 30 sec, and 72°C for 45 sec for all primers. These cycles were followed by 1 cycle of extension at 72°C for 10 min. Amplification products (10 microliters) were loaded on a 2% agarose gel in TBE buffer, stained with ethidium bromide, and directly visualized under UV illumination.

Results and Discussion

Caspase-8 western blot analysis of cell lysates from the NB8, NB10, and NB14 cell lines with (+) or without (-) 5-aza-2'-deoxycytidine. Surprisingly, other than the *CASP8* deletions, we found no evidence of mutations within *CASP8* coding regions in the NB cell lines (data not shown). We therefore examined DNA methylation of *CASP8* regulatory sequences as an alternative mechanism through which expression could be silenced, as documented for several tumor suppressor genes, such as *INK4a*, *CDKN1*, *CDKN2*, *PTEN*, *MLH1*, von Hippel-Lindau, and *E-cadherin* (Baylin *et al.*, Adv. Cancer Res., 1998, 72:141-196; Belinsky *et al.*, Proc. Natl. Acad. Sci. USA, 1998, 95:11891; Whang *et al.*, Proc. Natl. Acad. Sci. USA, 1998, 95:5246-5250; Merlo *et al.*, Nature Medicine, 1995, 1:686-692).

The role of methylation of *CASP8* regulatory sequences was tested by treating NB cells with 5-aza-cytidine, a compound that promotes the demethylation of CpG dinucleotides (Merlo *et al.*, Nature Medicine, 1995, 1:686-692). When cells were treated with 10-50 µM 5-aza-cytidine for 2-3 days, caspase-8 expression was activated in the NB8 and NB10 cell lines, but not NB14 (Figure 6A). The NB8 and NB10, but not NB14, cells then underwent spontaneous apoptosis, presumably due to the effect of caspase-8 in the presence of elevated N-myc levels (related to *MYCN* gene amplification).

The data show that a number of the neuroblastoma cell lines, in addition to having deletions, have turned off the expression of caspase-8 from the remaining allele by methylation of the promoter region. This seems to be a very common mechanism for extinguishing expression of the protein. This is also the reason the DNA sequence of the promoter region(s) is extremely important.

Investigation of *CASP8* promoter methylation using methylation-sensitive PCR

analysis. To test for methylation directly, a CpG-rich region of the *CASP8* 5' flanking region was chosen for the design of oligonucleotide primers for methylation sensitive-PCR analysis. In this assay, unmethylated cytosines, but not the methylated cytosines in CpG dinucleotides, are converted to uracils after sodium bisulfite treatment of genomic DNA (Herman *et al.*, Proc.Natl.Acad.Sci.USA, 1996, 93:9821-9826). Two separate pairs of oligonucleotide primers (21-23-mers) were designed. One primer set contained adenines substituted for each guanine in the antisense-strand, such that these primers only bind to bisulfite-modified DNA sequence corresponding to unmethylated DNA (SEQ ID NOS: 31, 32). The other primer set retained guanines at positions corresponding to cytosines in CpG dinucleotide sequences specific for methylated genomic DNA (SEQ ID NOS: 29, 30), since these residues are protected from bisulfite modification by methylation (Figure 6B). Using primers 31 and 32 for a PCR with bisulfite-treated genomic DNA from the NB cell lines as template, the 322-bp *CASP8* product was observed in NB3, NB5, NB15, NB16, and NB21, which express caspase-8, as well as the Jurkat and HeLa positive controls (Figure 6B). DNA sequence analysis of this product from NB16 revealed that all of the sense-strand cytosines within the 322-bp region were replaced with thymidine. When the same bisulfite-treated template DNA was used with the primers 29 and 30 a 321-bp PCR product was observed only in the NB cell lines that lacked caspase-8 expression, and in the NB3 that expresses caspase-8 at a low level (Figure 6B). DNA sequence analysis of the 321-bp product demonstrated that only sense-strand cytosines, that are not associated with a CpG dinucleotide, were replaced with thymidine. NB cell lines with two intact *CASP8* genes (*e.g.*, NB1, NB8, NB10) also showed evidence of no caspase-8 expression, indicating that both *CASP8* alleles were silenced by methylation. Interestingly, the NB cell lines continue to express caspase-10 from a closely linked gene (Figure 4D), arguing against global CpG dinucleotide methylation across this region of chromosome 2 band q33.

Cryopreserved primary neuroblastoma samples were examined to determine whether somatic cell loss of caspase-8 expression occurs in the tumor *in vivo* prior to tissue culture. A total of 42 samples were examined. In 11 of the 42 total samples analyzed, complete methylation of all *CASP8* alleles was observed. Representative examples are shown in Figure 7A. The PCR products of two patient samples correspond almost exclusively to methylated *CASP8*

alleles (*i.e.*, SJ-890191 and SJ-870015). In contrast, a PCR product corresponding predominantly to the unmethylated allele was detected in one of five patient samples, while the remaining two patient samples contained PCR products in reactions amplified with both primer sets. The results listed in Table 3 for all of the remaining NB patient samples were scored in an identical manner.

Semi-quantitative PCR was performed to determine whether these patient tumor cells expressed caspase-8 mRNA. For example, SJ-890191, as well as other patient samples with predominantly methylated *CASP8* alleles, did not express caspase-8 mRNA, whereas SJ-910008, and other patient samples with predominantly unmethylated, or a mixture of unmethylated and methylated, *CASP8* alleles, did express caspase-8 mRNA (Figures 7B and 7C).

TABLE 3

Analysis of Neuroblastoma Patient Tumors

Patient Sample	Stage	Methylated <i>CASP8</i> DNA	Unmethylated <i>CASP8</i> DNA	<i>CASP8</i> Deletion	<i>MYCN</i> Amplification
SJNB-920018	3	-	+	N	N
SJNB-910008	1	-	+	N	N
SJNB-890191	4	+	-	Y	Y
SJNB-910007	4	-	+	N	N
SJNB-930100	3	+	+	N	Y
SJNB-890175	3	+	+	N	Y
SJNB-870015	N/A	+	-	N	Y
SJNB-920017	N/A	+	+	N	N
SJNB-840065	1	-	+	N	N
SJNB-900106	4	+	-	N	Y
SJNB-970009	4	-	+	N	N
SJNB-960103	4	+	-	N	Y
SJNB-960051	1	+	+	N	N
SJNB-840089	N/A	-	+	N	N
SJNB-920063	3	-	+	N	N
POG-103	2	+	+	N	N
POG-158	2	-	+	N	N
POG-253	1	-	+	N	N
POG-429	3	+	+	N	N
POG-687	4	-	+	N	N
POG-770	4	+	+	N	N
POG-783	3	+	+	N	N
POG-840	4	+	-	N	Y
POG-1315	4	+	+	N	N
POG-1343	1	+	+	N	N
POG-1368	3	+	+	N	N
POG-1418	2	+	+	N	N

POG-1422	3	-	+	N	N
POG-1613	1	+	+	N	N
POG-2025	4S	-	+	N	N
POG-3087	4S	+	+	N	N
POG-3169	4	-	+	N	N
POG-4098	3	+	+	N	Y
POG-4177	4	-	+	N	Y
POG-4212	3	-	+	N	Y
POG-4316	4	+	-	N	Y
POG-4489	4	-	+	N	Y
POG-4499	4	+	-	N	Y
POG-4903	4	+	-	N	Y
POG-4911	4	+	-	N	Y
POG-5044	4	+	+	N	N
POG-5217	2	+	-	N	Y

Comprehensive analysis of the 42 NB patient samples revealed that complete methylation (*i.e.*, the absence of appreciable PCR product using the unmethylated DNA primer set) is most common in *MYCN* amplified neuroblastomas (Table 3). Ten of sixteen NB patient samples with *MYCN* amplification (63%), compared to only one of twenty-six samples without *MYCN* amplification (4%), contained completely methylated *CASP8* alleles. Deletions of 2q33 were not frequently detected in either group of patient samples using the BAC clone containing both *CASP8* and *CASP10*. Of possible interest, complete methylation, and therefore silencing, of *CASP8* did not occur in six of six late stage (*i.e.*, stage 4) neuroblastoma patient samples that did not contain amplified *MYCN* genes (Table 3; SJ- 910007, SJ-970009, POG-687, POG-770, POG-1315, POG-3169, POG-5044). Furthermore, complete methylation of *CASP8* occurred in one patient sample (*i.e.*, POG-5217; Table 3) from a stage two neuroblastoma with *MYCN* amplification.

Thus, silencing of *CASP8* by methylation appears to be almost exclusively associated with *MYCN* gene amplification in both the neuroblastoma patient samples and cell lines. This is the same sub-population of neuroblastoma patients known to have the poorest prognosis (Brodeur *et al.*, Cancer, 1992, 70:1685-1694) . Partial methylation of *CASP8* takes place in early stages of neuroblastoma, which might suggest that its methylation precedes the amplification of the *MYCN* gene.

EXAMPLE 4: The Use of Caspase-8 Overexpression to Determine the Functional Relevance of Caspase-8 Deficiency in Inhibition of Apoptosis and the Development of Cancer. The Use of Caspase-8 Overexpression as a Therapeutic Method to Sensitize Tumor Cells to Chemotherapeutic Drug Treatment

Materials and Methods

Expression constructs. The cell microinjection experiments employed a Fas receptor expression construct (Cheng *et al.*, Science, 1994, 263:1759-1761), a DR3 expression construct (Kitson *et al.*, Nature, 1996, 384:372-375), and an FADD and caspase-8(DN) expression constructs (Persons *et al.*, Blood, 1999, 93:488-499; Yeh *et al.*, Science, 1998, 279:1954-1958). Full-length wild type and dominant negative (DN) caspase-8 cDNAs were subcloned directly into pSP72 (Promega). Wild-type and DN caspase-8 cDNA inserts were then removed by *Cla I* and *Sal I* digestion from pSP72 and ligated into the *Nsp V* and *Xho I* sites of pMSCV-IGFP(M), respectively. Retrovirus supernatants were prepared as previously described (Persons *et al.*, Blood, 1999, 93:488-499). To prevent the spontaneous activation of caspase-8 during transfection, 50 mM zVAD-fmk was added into the cell culture medium. 2x10⁶ NB7, NB8 and NB10 cells were prepared the day before transduction in 10-mm culture dishes. 5 ml of the pMSCV-Casp8(wt) and pMSCV-Casp8(DN) viral soups were quickly thawed at 37°C and directly added to the cells and mixed gently with 5 ml of normal culture medium. 10 ml Polybrene (final concentration 4 mg/ml) was added into the culture medium and the cells incubated for 12-14 hrs at 37°C. After replacing this media with fresh viral soup and culture media, the cells were incubated at 37°C for an additional 48 hrs. The transduced cells were sorted out by GFP expression using FACS, and the GFP-positive cells placed back into cell culture incubator for next experiment. Standard immunoblotting using the caspase-8 mAb (C15) was performed to demonstrate that caspase-8 was expressed in the viral transduced NB7, NB8 and NB10 cells and normal NB7, NB8 and NB10 cells.

Apoptotic assays. Cells were collected for annexin V-FITC staining and FACS analysis after the culture media containing zVAD-fmk was removed and replaced with normal

culture medium for 6 hours in NB8 and NB10. For NB7, anti-FAS antibody (100ng/ml of CH-11) or TNFa (100 ng/ml) plus CHX (1 mg/ml) were then added to the cells and annexin-V-PE (PharMingen) staining performed as previously described (Tang *et al.*, J.Biol.Chem., 1999, 274:7245-7252). Cell survival assays were performed by standard trypan blue exclusion assay and analysis of nuclear DNA condensation by DAPI staining (Janicke *et al.*, Mol.Cell.Biol., 1994, 14:5661-5670). Viable cells were determined by light and immunofluorescent microscopy after removal of the zVAD-fmk containing culture medium and incubation at 37°C for 0.5, 1, 2, 4 and 6 hrs for the pMSCV-Casp 8(wt) and DN transduced NB8 and NB10 cells.

Results

To use caspase-8 as a target for anti-cancer therapy, it is essential to determine whether the loss of caspase-8 expression in the neuroblastoma cell lines is functionally relevant. All studied NB cell lines express either the Fas or DR3 receptors (Figure 5, Table 2, and Grenet *et al.*, Genomics, 1998, 49:385-393), both of which signal through FADD-dependent recruitment of caspase-8 (Kitson *et al.*, Nature, 1996, 384:372-375; Muzio *et al.*, Cell, 1996, 85:817-827). In addition, even though all of the NB cell lines express caspase-10 (Figure 4D), death receptor aggregation in response to Fas mAb or DR3 death receptor overexpression did not trigger cell death or result in caspase-10 processing (Table 4; data not shown).

TABLE 4

Apoptotic function of selected human neuroblastoma cell lines +/- caspase-8

CellLine	DR3-induced Apoptosis ¹	FADD-induced Apoptosis ¹	DR3/FADD-induced Apoptosis ¹	Caspase-8 protein	FasR protein	Doxorubicin-induced Apoptosis ²	Doxorubicin-induced Apoptosis (+caspase-8) ²
NB3	N/A	N/A	N/A	Y	Y	52 +/- 4%	-
NB5	N/A	N/A	N/A	Y	Y	54 +/- 4.6%	-
NB7	N	N	N	N	N	24 +/- 3%	42 +/- 2.6%
NB8	N	N	N	N	Y	18 +/- 2.6%	38 +/- 2%

- ¹ Apoptosis induced by overexpression of these proteins after microinjection of appropriate expression plasmids into NB7, NB8 and NB16. Apoptosis was assessed by TUNEL. N, less than 10% TUNEL-positive cells; Y, greater than 80% TUNEL-positive cells. Results represent three independent experiments.
- ² Apoptosis induced by treatment with 0.1 mM doxorubicin for 48 hrs, in three independent experiments, as described by others (Fulda *et al.*, Cancer Res., 1997, 57: 3823-3829). Percentage of cell death was determined by TUNEL.

To further examine the possible functional relevance of the caspase-8 deficiency, both Fas positive (NB8, NB10) and Fas negative (NB7) cell lines were transduced with a retroviral vector containing either wild-type caspase-8 (pMSCV-Casp8(wt)) or an inactive form of caspase-8 (pMSCV-Casp8(DN); Muzio *et al.*, Cell, 1996, 85:817-827). Caspase-8 expression programmed by the vector was verified by immunoblot analysis (Figure 8A). Since NB7, the cell line with homozygous *CASP8* deletion, does not express Fas receptor, an alternative death receptor was chosen to induce apoptosis. TNFR p55, a Fas-related death receptor, is expressed in NB7 cells, and when these cells were treated with TNF- α and cycloheximide (CHX) it promotes apoptosis only if retrovirally programmed caspase-8 is expressed and active (Yeh *et al.*, Science, 1998, 279: 1954-1958; Varfolomeev *et al.*, Immunity, 1998, 9: 267-276). Five hours after TNF- α /CHX treatment, approximately 5% of the NB7 cells lacking caspase-8 were apoptotic (Figure 8D), while approximately 40% of the pMSCV-Casp8(wt) cells had undergone apoptosis as judged by the condensed appearance of DAPI-stained nuclei (Figure 8C) and annexin-V-FITC staining (Figure 8D). Expression of high levels of wild-type caspase-8, but not caspase-8(DN), in NB8 and NB10 cells resulted in 60-65% cell death in the absence of apoptotic stimuli (Figure 8D). When stable NB8 and NB10 cell populations expressing lower, non-lethal, levels of caspase-8 were selected, they did not undergo significant apoptosis in the absence of an appropriate stimulus (Figure 8E). However, addition of agonistic Fas mAb to NB8 culture media resulted in greater than 98% cell death within six hours (Figure 8E). If the potent caspase inhibitor zVAD-fmk (Milligan *et al.*, Neuron, 1995, 15:385-393) was added to the cell culture media prior to programmed expression of caspase-8, apoptosis induced by agonistic Fas mAb was blocked in both cell lines no matter what the level of caspase-8 expression (Figures 8D and 8E).

Although the participation of caspase-8 in tumor cell death induced by
chemotherapeutic drug treatment has been considered a controversial issue, it has been suggested
that both Fas/CD95-dependent and independent activation of caspase-8 is involved (Landowski *et al.*,
Blood, 1999, 94:265-274; Fulda *et al.*, Cancer Res., 1997, 57:3823-3829). In further support
of this, we found that NB cell lines (*e.g.*, NB16 and NB21) expressing caspase-8 are more
sensitized to doxorubicin-induced apoptosis, whereas cell lines that do not express caspase-8 are
not sensitized, regardless of their Fas/CD95 expression status (Table 4). In order to determine
whether exogenous expression of caspase-8 resensitized caspase-8 null NB cells to
chemotherapeutic agents, NB7 cells and NB7 cells transduced with pMSCV-Casp8(wt) were
treated with doxorubicin. Doxorubicin-induced neuroblastoma apoptosis has previously been
linked to the Fas receptor pathway (Fulda *et al.*, Cancer Res., 1997, 57:3823-3829). The NB7
cell line was chosen since it lacks a functional *CASP8* gene (Figures 4 and 5, Table 2). While the
parental NB7 cells, as well as those transduced with pMSCV or pMSCV-Casp8(DN), underwent
very limited apoptosis after exposure to low levels of doxorubicin, those expressing functional
caspase-8 underwent a 70-100% increase in the level of cell death (Table 4). Thus, NB7 cells
expressing functional caspase-8 are resensitized to treatment with doxorubicin, demonstrating that
caspase-8 expression and activation are capable of accelerating NB7 cell apoptosis and that
caspase-8 is functionally relevant to this form of cell death.

Discussion

These data suggest that inactivation of the Fas apoptotic pathway through
epigenetic modification of caspase-8 expression contributes to the survival of many
neuroblastoma cells that acquire high levels of Myc-N through gene amplification. Caspase-8 has
been shown to play a pivotal role in apoptosis induced by activated death receptors (Askew *et al.*,
Oncogene, 1991, 6: 1915-1922; Kitson *et al.*, Nature, 1996, 384: 372-375), chemotherapeutic
drugs (*e.g.*, doxorubicin) and irradiation (Friesen *et al.*, Nature Med., 1996, 2: 574-577; Fulda *et al.*,
Cancer Res., 1997, 57: 3823-3829). In at least one NB cell line, loss of caspase-8 expression
appears to contribute to reduced levels of doxorubicin-induced apoptosis, as well as the
dysregulated proliferation, that characterize *MYCN* amplified neuroblastoma.

The results of the present studies further suggest that an analysis of *CASP8* methylation status, particularly in tumors overexpressing myc oncoproteins, might prove to be a useful diagnostic tool. Caspase-8 gene transfer studies, the use of specific demethylating agents, and/or the use of specific methylase inhibitors may also need to be considered as potential treatments for neuroblastomas with *MYCN* amplification. Augmentation of chemotherapeutic/irradiation treatment regimens in this manner might enhance their effectiveness, thereby improving the prognosis for these patients.

* * *

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, are approximate, and are provided for description.

Patents, patent applications, procedures, and publications cited throughout this application are incorporated herein by reference in their entireties.

WHAT IS CLAIMED IS:

1 1. A method for detecting inactivation of a *CASP8* gene, comprising detecting
2 a modification of genomic DNA comprising the *CASP8* gene, wherein such a modification results
3 in inactivation of a *CASP8* gene.

1 2. The method according to claim 1, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is detected by detecting the absence of a CASP8
3 protein in a sample from a cell.

1 3. The method according to claim 2, wherein the absence of a CASP8 protein
2 is detected by a method selected from the group consisting of immunoassay and biochemical
3 assay.

1 4. The method according to claim 1, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is methylation of *CASP8* promoter.

1 5. The method according to claim 4, wherein methylation of the *CASP8*
2 promoter is detected by methylation polymerase chain reaction (PCR) assay.

1 6. The method according to claim 1, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is a mutation in the *CASP8* genomic gene.

1 7. The method according to claim 6, wherein the mutation is selected from the
2 group consisting of an insertion in the gene, a deletion of the gene, a truncation of the gene, a
3 nonsense mutation, a frameshift mutation, a splice-site mutation, and a missense mutation.

1 8. The method according to claim 6, wherein the mutation is a deletion in the
2 *CASP8* gene.

1 9. The method according to claim 8, wherein deletion of the *CASP8* gene is
2 detected with a labeled nucleic acid probe.

1 10. A method for diagnosis or prognosis of a cancer comprising detecting
2 inactivation of a *CASP8* gene, wherein inactivation of the *CASP8* gene is indicative of the
3 presence of a cancer or a poor prognosis.

1 11. The method according to claim 10, wherein the cancer is a tumor in which
2 a *myc* gene is amplified.

1 12. The method according to claim 10, wherein the cancer is a neuroblastoma.

1 13. The method according to claim 10, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is detected by detecting the absence of a *CASP8*
3 protein in a sample from a cell.

1 14. The method according to claim 13, wherein the absence of a CASP8
2 protein is detected by a method selected from the group consisting of immunoassay and
3 biochemical assay.

1 15. The method according to claim 10, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is methylation of *CASP8* promoter.

1 16. The method according to claim 15, wherein methylation of the *CASP8*
2 promoter is detected by methylation polymerase chain reaction (PCR) assay.

1 17. The method according to claim 10, wherein the modification of genomic
2 DNA resulting in inactivation of a *CASP8* gene is a mutation in the *CASP8* genomic gene.

1 18. The method according to claim 17, wherein the mutation is selected from
2 the group consisting of an insertion in the gene, a deletion of the gene, a truncation of the gene, a
3 nonsense mutation, a frameshift mutation, a splice-site mutation, and a missense mutation.

1 19. The method according to claim 17, wherein the mutation is a deletion in the
2 *CASP8* gene.

1 20. The method according to claim 19, wherein deletion of the *CASP8* gene is
2 detected with a labeled nucleic acid probe.

1 21. A nucleic acid comprising at least a part of the genomic gene encoding
2 *CASP8*, wherein the nucleic acid is selected from the group consisting of:

- 3 a) a *CASP8* genomic DNA;
- 4 b) a *CASP8* promoter;
- 5 c) a nucleic acid amplified by primers that correspond to a sequence
6 selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,
7 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28;
- 8 d) a *CASP8* exon;
- 9 e) a *CASP8* intron;
- 10 f) a nucleic acid having at least 15 bases and hybridizable under
11 stringent conditions to a *CASP8* non-coding sequence.

1 22. The nucleic acid according to claim 21 which is a *CASP8* genomic DNA
2 having a nucleic acid sequence as depicted in SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, or 10.

1 23. The nucleic acid according to claim 21 which is a *CASP8* promoter having
2 a nucleic acid sequence as depicted in SEQ ID NO: 1 or 2.

1 24. The nucleic acid according to claim 21 which is an oligonucleotide that
2 hybridizes to the *CASP8* promoter, wherein the oligonucleotide is a PCR primer for the promoter.

1 25. The nucleic acid according to claim 21 which is an oligonucleotide having
2 at least 15 bases and hybridizable under stringent conditions to a *CASP8* non-coding sequence,
3 which oligonucleotide is labeled.

1 26. A kit for detecting inactivation of a *CASP8* gene comprising a detection
2 assay for inactivation of a *CASP8* gene.

27. The kit of claim 26, wherein the detection assay is an immunoassay.

28. The kit of claim 26, wherein the detection assay comprises oligonucleotide
PCR primers for amplification of at least a part of *CASP8* genomic DNA.

1 29. The kit of claim 26, wherein the detection assay comprises a labeled
2 oligonucleotide of at least 15 bases that specifically hybridizes to *CASP8* genomic DNA.

1 30. A method of treating a cancer in a subject comprising administering an
2 amount of a vector that expresses a gene encoding functional CASP8 effective to express a
3 functional level of CASP8 into cells of the subject.

1 31. The method according to claim 30, wherein the cancer is a tumor in which
2 a *myc* gene is amplified.

1 32. The method according to claim 30, wherein the cancer is a neuroblastoma.

1 33. The method according to claim 30, wherein a *CASP8* gene is inactivated in
2 tumor cells of the cancer.

34. The method according to claim 30, wherein the vector comprises a
promoter that provides for high level expression operatively associated with the gene encoding a
functional CASP8, whereby the functional CASP8 is expressed at high levels.

35. The method according to claim 30, wherein the vector is selected from the
group consisting of a defective herpes virus (HSV) vector, a defective adenovirus vector, and a
non-viral vector.

1 36. A vector that expresses a gene encoding functional human CASP8 in
2 human target cells.

1 37. The vector of claim 36 comprising a promoter that provides for high level
2 expression operatively associated with the gene encoding a functional CASP8, whereby the
3 functional CASP8 is expressed at high levels.

1 38. A pharmaceutical composition for treating a cancer comprising the vector
2 of claim 32 and a pharmaceutically acceptable carrier.

1 39. A method of screening for a candidate compound that induces death-
2 receptor-mediated apoptosis in cells where a *CASP8* gene is inactivated, comprising contacting
3 cells in which a *CASP8* gene is inactivated with a candidate compound and detecting whether the
4 cell undergoes apoptosis.

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209

1 results from a mutation in the *CASP8* genomic gene.

1 45. A kit for screening for a candidate compound that induces death-receptor-
2 mediated apoptosis in cells where a *CASP8* gene is inactivated, comprising cells in which a
3 *CASP8* gene is inactivated and a detection assay for whether the cell undergoes apoptosis.

1 46. The kit of claim 45, wherein inactivation of the *CASP8* gene results from
2 methylation of *CASP8* promoter.


47. The kit of claim 45, wherein inactivation of the *CASP8* gene results from a
mutation in the *CASP8* genomic gene.

660627-280460

ABSTRACT

The present invention relates to identification of tumor suppressor activity of a protein, caspase-8 (CASP8), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter. In particular, *CASP8* is functionally inactivated in greater than 90% of all *MYCN* amplified neuroblastoma cell lines analyzed. Inactivation of *CASP8* was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. A PCR methylation analysis for inactivation of *CASP8* is described.

10
560627-2302460



caspase 8 β 4
 caspase 8 β 3
 caspase 8 α 3
 caspase 8 α 2
 caspase 8 α 1

ex 1, (133 bp)
 ex 2, (97 bp)
 ex 3, (333 bp)
 ex 4, (106 bp)
 ex 5, (138 bp)
 ex 6, (45 bp)
 ex 7, (66 bp)
 ex 8, (142 bp)
 ex 9, (502 bp)
 ex 10, (>2 kb)




FIGURE 1

- ⋮ = Exon boundary
- ▨ = DED
- = Large caspase subunit
- ▤ = Small caspase subunit
- ▩ = CASP10

FIGURE 2






FIGURE 3A



660627 2302460


FIGURE 3B



Chromosome 2


C.

Deleted *CASP8* allele



D.

Normal *CASP8* allele




660227 23022460


FIGURE 4
Teitz et al.

660627" 2302460

A.



B.






FIGURE 4





FIGURE 4

FIGURE 5
Teitz et al.



A.




FIGURE 6

B.






FIGURE 6

A.



B.



C.






FIGURE 8
Teitz et al.

A.




B.




C.

D.



F.

FIGURE 8
Teitz et al.

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor if only one name is listed at 1 below, or a joint inventor if plural inventors are named below, of the invention entitled:

which is described and claimed in:

that I do not know and do not believe that the same was ever known or used in the United States of America before my or our invention thereof or patented or described in any printed publication in any country before my or our invention thereof, or more than one year prior to this application, or in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months prior to this application, that I acknowledge my duty to disclose information of which I am aware which is material to patentability in accordance with 37 CFR §1.56. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

PRIOR APPLICATION(S), IF ANY, OF WHICH PRIORITY IS CLAIMED

DATE OF FILING

December 31, 1998

**ALL FOREIGN APPLICATIONS, IF ANY, FILED PRIOR
TO THE APPLICATION(S) OF WHICH PRIORITY IS CLAIMED**

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DATE OF FILING</u>
----------------	------------------------	-----------------------

POWER OF ATTORNEY:

As a named inventor, I hereby appoint the following attorney(s) and/or agents(s) to prosecute this application and transact all business in the Patent and Trademark office connected therewith: Gordon D. Coplein #19,165, William F. Dudine, Jr. #20,569, Michael J. Sweedler #19,937, S. Peter Ludwig #25,351, Paul Fields #20,298, Harold E. Wurst #22,183, Joseph B. Lerch #26,936, Melvin C. Garner #26,272, Ethan Horwitz #27,646, Beverly B. Goodwin #28,417, Adda C. Gogoris #29,714, Martin E. Goldstein #20,869, Bert J. Lewen #19,407, Henry Sternberg #22,408, Robert A. Green #28,301, Peter C. Schechter #31,662, Robert Schaffer #31,194, Robert C. Sullivan, Jr. #30,499, Ira J. Levy #35,587, Joseph R. Robinson #33,448, Paul F. Fehlner, #35,135

all of the firm of DARBY & DARBY P.C., 805 Third Avenue, New York, NY 10022

SEND CORRESPONDENCE TO:

DARBY & DARBY P.C.
805 Third Avenue
New York, NY 10022

DIRECT TELEPHONE CALLS TO:

Paul F. Fehlner, Ph.D.

212-527-7700

FULL NAME AND RESIDENCE OF INVENTOR 1

LAST NAME: KIDD FIRST NAME: Vincent MIDDLE NAME: J.

CITY: Memphis STATE OR FOREIGN COUNTRY: Tennessee COUNTRY OF CITIZENSHIP: United States

POST OFFICE ADDRESS: 110 Plantation Woods Cove CITY: Memphis STATE OR COUNTRY: Tennessee ZIP CODE: 38108

FULL NAME AND RESIDENCE OF INVENTOR 2

LAST NAME: LAHTI FIRST NAME: JIII MIDDLE NAME: M.

CITY: Memphis STATE OR FOREIGN COUNTRY: Tennessee COUNTRY OF CITIZENSHIP: United States

POST OFFICE ADDRESS: 110 Plantation Woods Cove CITY: Memphis STATE OR COUNTRY: Tennessee ZIP CODE: 38108

FULL NAME AND RESIDENCE OF INVENTOR 3

LAST NAME: TEITZ FIRST NAME: Tai MIDDLE NAME:

CITY: Cordova STATE OR FOREIGN COUNTRY: Tennessee COUNTRY OF CITIZENSHIP: Israel

POST OFFICE ADDRESS: 7579 Cordova Club Drive CITY: Cordova STATE OR COUNTRY: Tennessee ZIP CODE: 38018

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1: _____ DATED: _____
Vincent J. KIDD

SIGNATURE OF INVENTOR 2: _____ DATED: _____
Jill M. LAHTI

SIGNATURE OF INVENTOR 3: _____ DATED: _____
Tal TEITZ

(D&DForms/PTO-21)

REV. 12/87

1E988-SEQLIST

SEQUENCE LISTING

<110> Kidd, Vincent J. et al.

<120> A Tumor Suppressor Protein Involved in
Death Signaling, and Diagnostics, Therapeutics, and
Screening Based on This Protein

<130> 2427/1E988-US1

<140> Pending

<141> 1999-12-30

<150> 60/114,308

<151> 1998-12-31

<160> 34

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 670

<212> DNA

<213> Human

<400> 1

aagcgctcca	agacacgatt	gcagaaggaa	cacgggggtgg	ccaactgaaa	tttgaagaac	60
agggccaagg	atgggaactc	agcctgagca	cgggttgatc	cggagcaggg	ctaagccaag	120
tacgaatgaa	ccagaccact	tcctcctttt	tttctgaacg	atctaccgcg	atttcagcca	180
cagggctgac	tttaccagct	cgggcgggag	ggaggagagg	gctgggtctgt	gacttcagtg	240
ctgaggtttg	atcaaggcaa	agggaaactt	cctattccca	gaccctttgc	aagaaagaat	300
ggcatattac	ttgccgccga	caggggttat	tattactaaa	tggagtcagt	ataaatgctt	360
tccaataaag	catgtccagc	gctcgggctt	tagtttgcac	gtccatgaat	tgtctgccac	420
atccctcttc	tgaatggttg	gaattgggca	tctctgttcc	tttaaacagg	aaacatttct	480
tgttcgagtg	agtcattctt	gttctgcttt	aggagtaaag	tttaccctgc	agttccttct	540
gtggtgaagt	tttctctttc	tctcggagac	cagattctgc	ctttacgctg	gaggggaagt	600
ttttcacagg	ttctctctct	tttatctttt	gtgttttttt	tcgagccatg	gggggttaaat	660
aaagcgcttt						670

<210> 2

<211> 753

<212> DNA

<213> Human

<400> 2

aattagaccg	cgtattgaaa	gtaaaagaaa	cttcttctctg	ggagcctttc	ccacccctt	60
ccctgctgag	cacgtggagt	taggcagggt	aggggactcg	gagactgcga	tggtgccagg	120
aaaggggtga	gcgggtgagt	gcctgttgcc	aaggtggcct	cttcaacagg	aaaccacaat	180
atTTTTgttt	cttgacttgc	tctagaaaca	gggctgtggg	ggtggggaag	caacttggat	240
ctgcccttct	gaggacacct	ctgggtgctgc	ctggcccagg	tctcctgtgt	ggtttctctc	300
tgagccgatg	cctttgactt	tgctactttt	tcactctgag	cagtctccag	ttcctctgct	360

1E988-SEQLIST

acctttttgt	cctccaagct	tccctgccgc	ctcgaatgca	gatacacgga	ctcccttctg	420
tggacccgtt	tggagagtcc	agaagacttt	atcaatccac	ttttttttct	ttttcatttg	480
gccctggggg	ccgacgggta	agtactttat	tctgtcattc	tgtcgaatca	cgaatgccct	540
gaggtgcaca	gcccctttcc	cctctttcgc	gtcctgaagg	ggtttccttt	tatgtcttcc	600
acccccaccc	tttccctctc	ctgccctctg	tttttgttgc	ccaaaaaaca	agttctctaa	660
acgttttoga	tgtggattcg	cggaaaatta	acctgcaccc	gtttgcaaaa	tgaacttttt	720
ttttttgatc	ctgtacactg	gttttttaac	ctt			753

<210> 3
 <211> 879
 <212> DNA
 <213> Human

<400> 3						
ccaccgcgcc	cagcccattg	gcttggtttgt	atgtctacct	tcctaaacag	taagagggaa	60
cttgtctggt	gttctttttt	tctctcctgt	gctgacagca	caatgaccag	tacctagtag	120
ttgcagtagc	ctttgatgaa	caagccagca	aatggtactt	ttcttcctta	tctgaacata	180
ccatttatatt	tgacttagat	tatattctcc	tgccctttta	aaagatggac	ttcagcagaa	240
atctttatga	tattggggaa	caactggaca	gtgaagatct	ggcctccctc	aagttcctga	300
gcctgaacta	cattccgcaa	aggaagcaag	aacccatcaa	ggatgccttg	atgttattcc	360
agagacycca	ggaaaagaga	atgtttggagg	aaagcaatct	gtccttcctg	aaggagctgc	420
tcttccgaat	taatagactg	gatttgctga	ttacctacct	aaacactaga	aaggaggaga	480
tggaaaggga	acttcagaca	ccaggcaggg	ctcaaatttc	tgccctacagg	tgggtggaaa	540
ctcccatgtg	gggactggga	ggtgtgggtt	gaatggacag	cctctgagct	gattggggct	600
tttttttgtg	gtaccctgcc	tagtgcctgg	gaaccagca	gtgccacaat	tctaaagctt	660
ctacagaaga	cagtagtgcc	ttggtggtcc	tgctaaaggc	tgtaaaactt	agcttctccc	720
caccctagag	agagtgggta	aacaaaggcg	tgagagagaa	accaacattc	agtatcactt	780
gggaggcttt	gggaagatgt	cccaccggag	ccagattaag	aaatttaggg	gccttatata	840
taattctata	gaaatgctaa	gaccataaaa	taaaaattt			879

<210> 4
 <211> 659
 <212> DNA
 <213> Human

<400> 4						
ccgcgcgttg	gccgattcat	taatgcagct	ggcacgcagg	tttcccact	ggaaaagcgg	60
gcagtgagcg	caacgcaatt	aatgtgagtt	agtcactctt	aggcactcca	tggcccatgc	120
cattactggc	tttatgttga	gggtggcctt	tgggatccga	gccccctgtg	gctccatata	180
tcacatggga	cttatttggc	caagattttc	aaagtgtctc	catttcccaa	ccacaaaggg	240
tcatgtctta	tcagatttca	gaagaagtga	gcagatcaga	attgaggtct	tttaagtttc	300
ttttgcaaga	ggaaatctcc	aaatgcaaac	tggatgatga	catggtgcct	gggaacagca	360
ggccacaatt	ctaagcttct	acagaaaaga	cagtagtgcc	ttgggtggcc	tgctaaaggc	420
tgtaaaaactt	agcttctccc	caccctagag	agagtgggta	aacaaaggcg	tgagagagaa	480
accacattca	gtatcacttg	ggaggctttg	ggaagatgtc	ccaccggagc	cagattaaga	540
aatttagggg	ccttatatat	aattctatag	aaatgctaag	accataaaat	aaaaatttat	600
ttttcaaagt	gaaacattac	ttagaggtat	gctgaagtta	taatagagtt	tttctaagt	659

<210> 5
 <211> 448
 <212> DNA
 <213> Human

[illegible]

<400> 5						
ggggactggg	tgacatctga	catggcttct	cctttatcct	ctcacttctg	tctttctggg	60
ccagaaaaca	tggaatcgct	tccctagtag	cctgctggct	gtgagagacc	agcagaaaact	120
gtcagaaaact	tgggaagcaa	gggcaggtcc	ttggttggag	aaattggaaa	ttaaaaaaaaa	180
aaatctaata	taaaaaccag	tagggctcaa	tcagattcca	actttatttc	tcctcctctt	240
acaacctgct	ggatatatttc	atagagatgg	agaagagggt	catcctggga	gaaggaaagt	300
tggacatcct	gaaaagagtc	tgtgcccaaa	tcaacaagag	cctgctgaag	ataatcaacg	360
actatgaaga	attcagcaaa	gtaccgcaat	ttcctatggt	ttaacgcagc	ataggtcaga	420
agggggcctg	cgcagctcga	taatctgg				448

<213> Human

<400> 6						
cccgcctcta	ctaagttttg	atagctggca	aaatcggcta	ccatatcaca	ggtgttttta	60
gtcaactgtt	gttcgggggt	accctttgcc	ttatctgagg	agagaagcag	cagccttgaa	120
ggaagtcctg	atgaattttc	aaatgttagt	taatttacta	tctggtacct	gcatgtgttc	180
tcccttcagc	cttctaccac	atgcacatct	taacgtgcct	gctctact		228

<213> Human

<400> /						
cggggtcacc	ttggggtaaa	ttttcccg	ttttcccgag	ggggaggagt	tgtgtgggg	60
aatgacaatc	tcggaacttc	caagagaaca	ggatagtga	tcccaggtag	cacggaaaac	120
ctccaaatcc	ttttttttac	attacattac	agattctagt	tttttaattt	gtagct	177

<213> Human

<400> 8						
aatattaata	tatgtgcaaa	gtgctcagga	ggcccaggta	ttgggacact	gactttacaa	60
cgatggggca	gaagtctgag	aggtcctgtg	tgaaggaaat	aggtagaaac	tagttcttcg	120
aggaaacgac	cccgagtttg	ggtggtgcaa	tggaaagcaa	gtcctcttac	tagggagttg	180
tttgtttaca	tctctagtgt	ttgaccacaa	gagtcagctc	ctgggttggt	tttttgtaat	240
ccagactttg	gacaaaagttt	accaaatgaa	aagcaaacct	cggggatact	gtctgatcat	300
ccaacaatca	caattttgca	aaagcacggg	agaaagtgcc	caaacttcac	agcattaggg	360
acaggaatgg	aacacacttg	gatgcaggtg	ggcggggctc	gtgagcgtgc	cttccaaatt	420
cccccaaatg	ggagaaaatc	cttcttatgc	ctattttttt	ttaaatacaa	agggatttaa	480
catagctata	ccaaaagggc	catggttcaa	gaaaatggat	ttaaacatat	ttccctgtgg	540
aggtaagaa	cattcttata	catttatcag	tttctgtctt	tttttaaaaa	ttaatttttt	600
aaataaaagt	aatgtatgta	taaatataaa	atatcaaadc	ttactaaaag	acataatgaa	660
aagcagtaat	aagctttgtt	ttgaattcag	ctaaatgcat	agcgtctctg	tggaaatgtat	720
taggcgatga	aaatgctggg	gggatcaaa	ccttatagag	gctgcatttt	tacaggttgg	780
gctg						784

Page 3

1E988-SEQLIST

<211> 771
 <212> DNA
 <213> Human

<400> 9

ggtcctttgc	ttgtctctcg	gtgtcctgca	ctctccctct	cctgctggtc	tgtgcttgct	60
atagtgtggc	gtactgttcg	agtttcactt	ttcaggggct	ttgaccacga	ctttgaagag	120
cttcattttg	agatcaagcc	ccacgatgac	tgcacagtag	agcaaatacta	tgacattttg	180
aaaatctacc	aactcatgga	ccacagtaac	atggactgct	tcatctgctg	tatcctctcc	240
catggagaca	agggcatcat	ctatggcact	gatggacagg	agccccccat	ctatgagctg	300
acatctcagt	tacttggttt	gaagtgcctt	tcccttgctg	gaaaacccaa	agtgtttttt	360
attcaggatt	gtcaggggga	taactaccag	aaaggtatac	ctgttgagac	tgattcagag	420
gagcaaccct	atttagaaat	ggatttatca	tcacctcaaa	cgagatatat	cccggatgag	480
gctgactttc	tgctggggat	ggccactgtg	aataactgtg	ttcctaccga	aaccctgcag	540
agggaaacctg	gtacatccag	tcactttgcc	agagcctgag	agagcgatgt	cctcggtaag	600
ttttgcctac	tcagccctcc	tcactgttac	actaccttcc	ccccctactc	catcacacta	660
ctatctactc	atattcagag	cctattagaa	agtgtctatgt	gatttagatc	acattaacag	720
gtcagagaac	tgtccaaggg	gagtggtttc	cgttcaactc	taaatgtcta	g	771

<210> 10
 <211> 223
 <212> DNA
 <213> Human

<400> 10

cttcgtggtc	tgtctctggg	cccgcaggcc	cccagttctc	cgtgctttcc	ccctcagccg	60
tcgcaatagt	gtgtgaatag	tttgcagagg	cgatgatatt	ctcaccatcc	tgactgaagt	120
gaactatgaa	gtaagcaaca	aggatgacaa	gaaaaacatg	gggaaacaga	tgccctcagcc	180
tactttcaca	ctaagaaaaa	aacttgtctt	cccttctgat	tga		223

<210> 11
 <211> 5
 <212> PRT
 <213> Human

<400> 11

Gln	Ala	Cys	Xaa	Gly
1				5

<210> 12
 <211> 8
 <212> PRT
 <213> Human

<400> 12

Arg	Asn	Pro	Ala	Glu	Gly	Thr	Trp
1					5		

<210> 13
 <211> 20
 <212> DNA
 <213> Human

1E988-SEQLIST

<400> 13
ggtggagcgg gtgtgggtcg 20

<210> 14
<211> 23
<212> DNA
<213> Human

<400> 14
tattttgact tagattatat tct 23

<210> 15
<211> 22
<212> DNA
<213> Human

<400> 15
gcctacaggt ggggtggaaac tc 22

<210> 16
<211> 20
<212> DNA
<213> Human

<400> 16
cccaaccaca aagggtcatg 20

<210> 17
<211> 21
<212> DNA
<213> Human

<400> 17
gatgacatgg tgcctgggaa c 21

<210> 18
<211> 21
<212> DNA
<213> Human

<400> 18
ttctcctcct cttacaacct g 21

<210> 19
<211> 22
<212> DNA
<213> Human

<400> 19
ttcagcaaag taccgcaatt tc 22

<210> 20
<211> 21

1E988-SEQLIST

<212> DNA
<213> Human

<400> 20
tttgccttat ctgaggagag a 21

<210> 21
<211> 23
<212> DNA
<213> Human

<400> 21
tcaaattgta gttaatttac tat 23

<210> 22
<211> 23
<212> DNA
<213> Human

<400> 22
tcccggggttt tcccgagggg gag 23

<210> 23
<211> 21
<212> DNA
<213> Human

<400> 23
tcacaggtag cacggaaaac c 21

<210> 24
<211> 22
<212> DNA
<213> Human

<400> 24
gggttttgta atccagactt tg 22

<210> 25
<211> 20
<212> DNA
<213> Human

<400> 25
gatgcaggtg ggcgggggctc 20

<210> 26
<211> 23
<212> DNA
<213> Human

<400> 26
agtttcactt ttcaggggct ttg 23

1E988-SEQLIST

<210> 27
 <211> 24
 <212> DNA
 <213> Human

<400> 27
 tgcctcggg aagttttgcc tact 24

<210> 28
 <211> 22
 <212> DNA
 <213> Human

<400> 28
 gtgaatagtt tgcagaggcg at 22

<210> 29
 <211> 21
 <212> DNA
 <213> Human

<400> 29
 taggggattc ggagattgag a 21

<210> 30
 <211> 22
 <212> DNA
 <213> Human

<400> 30
 cgtatatcta cattcgaaac ga 22

<210> 31
 <211> 21
 <212> DNA
 <213> Human

<400> 31
 taggggattt ggagattgtg a 21

<210> 32
 <211> 25
 <212> DNA
 <213> Human

<400> 32
 ccatatatat ctacattcaa aacaa 25

<210> 33
 <211> 21
 <212> DNA
 <213> Human

1E988-SEQLIST

<400> 33
taggggactc ggagactgcg a 21

<210> 34
<211> 21
<212> DNA
<213> Human

<400> 34
cgtgtatctg cattcgaggc g 21

660227"2302460